{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:51:59Z","timestamp":1791582719138,"version":"4.3.4"},"reference-count":265,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s12072-025-10838-y","type":"journal-article","created":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T21:37:33Z","timestamp":1751319453000},"page":"732-759","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Decoding the hepatic fibrosis-hepatocellular carcinoma axis: from mechanisms to therapeutic opportunities"],"prefix":"10.1007","volume":"19","author":[{"given":"Anqi","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minying","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bufu","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyi","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaoqu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"10838_CR1","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/S2468-1253(16)30205-9","volume":"2","author":"R Harris","year":"2017","unstructured":"Harris R, Harman DJ, Card TR, Aithal GP, Guha IN. Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review. Lancet Gastroenterol Hepatol. 2017;2:288\u2013297","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10838_CR2","doi-asserted-by":"publisher","first-page":"S199","DOI":"10.3350\/cmh.2024.0351","volume":"30","author":"HY Kim","year":"2024","unstructured":"Kim HY, Yu JH, Chon YE, Kim SU, Kim MN, Han JW, et al. Prevalence of clinically significant liver fibrosis in the general population: a systematic review and meta-analysis. Clin Mol Hepatol. 2024;30:S199-213","journal-title":"Clin Mol Hepatol"},{"key":"10838_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2024.102610","volume":"92","author":"A Arnett","year":"2024","unstructured":"Arnett A, Siegel DA, Dai S, Thompson TD, Foster J, di Pierro EJ, et al. Incidence and survival of pediatric and adult hepatocellular carcinoma, United States, 2001\u20132020. Cancer Epidemiol. 2024;92: 102610","journal-title":"Cancer Epidemiol"},{"key":"10838_CR4","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u2013263","journal-title":"CA Cancer J Clin"},{"key":"10838_CR5","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1056\/NEJMra1001683","volume":"365","author":"HB El-Serag","year":"2011","unstructured":"El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365:1118\u20131127","journal-title":"N Engl J Med"},{"key":"10838_CR6","first-page":"77","volume":"21","author":"G Fattovich","year":"1995","unstructured":"Fattovich G, Giustina G, Schalm SW, Hadziyannis S, Sanchez-Tapias J, Almasio P, et al. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatol Baltim Md. 1995;21:77\u201382","journal-title":"Hepatol Baltim Md."},{"key":"10838_CR7","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1053\/j.gastro.2004.09.014","volume":"127","author":"G Fattovich","year":"2004","unstructured":"Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127:S35-50","journal-title":"Gastroenterology"},{"key":"10838_CR8","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.1002\/cncr.28832","volume":"120","author":"JA Flemming","year":"2014","unstructured":"Flemming JA, Yang JD, Vittinghoff E, Kim WR, Terrault NA. Risk prediction of hepatocellular carcinoma in patients with cirrhosis: the ADRESS-HCC risk model. Cancer. 2014;120:3485\u20133493","journal-title":"Cancer"},{"issue":"Suppl 1","key":"10838_CR9","volume":"6","author":"V Chavda","year":"2023","unstructured":"Chavda V, Zajac KK, Gunn JL, Balar P, Khadela A, Vaghela D, et al. Ethnic differences in hepatocellular carcinoma prevalence and therapeutic outcomes. Cancer Rep Hoboken NJ. 2023;6(Suppl 1): e1821","journal-title":"Cancer Rep Hoboken NJ"},{"key":"10838_CR10","doi-asserted-by":"publisher","first-page":"e130","DOI":"10.1002\/imt2.130","volume":"2","author":"L Liu","year":"2023","unstructured":"Liu L, Xie Y, Yang H, Lin A, Dong M, Wang H, et al. HPVTIMER: a shiny web application for tumor immune estimation in human papillomavirus-associated cancers. iMeta. 2023;2:e130","journal-title":"iMeta."},{"key":"10838_CR11","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.toxrep.2021.02.010","volume":"8","author":"V Subramaniyan","year":"2021","unstructured":"Subramaniyan V, Chakravarthi S, Jegasothy R, Seng WY, Fuloria NK, Fuloria S, et al. Alcohol-associated liver disease: a review on its pathophysiology, diagnosis and drug therapy. Toxicol Rep. 2021;8:376\u2013385","journal-title":"Toxicol Rep"},{"key":"10838_CR12","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1002\/hep.29546","volume":"67","author":"AM Allen","year":"2018","unstructured":"Allen AM, Therneau TM, Larson JJ, Coward A, Somers VK, Kamath PS. Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: a 20 year-community study. Hepatol Baltim Md. 2018;67:1726\u20131736","journal-title":"Hepatol Baltim Md"},{"key":"10838_CR13","first-page":"1342","volume":"10","author":"DL White","year":"2012","unstructured":"White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2012;10:1342-1359.e2","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"key":"10838_CR14","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1053\/j.gastro.2005.04.014","volume":"129","author":"LA Adams","year":"2005","unstructured":"Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005;129:113\u2013121","journal-title":"Gastroenterology"},{"key":"10838_CR15","doi-asserted-by":"publisher","first-page":"E7","DOI":"10.1038\/s41586-021-04104-y","volume":"600","author":"AL Correia","year":"2021","unstructured":"Correia AL, Guimaraes JC, Auf der Maur P, De Silva D, Trefny MP, Okamoto R, et al. Author correction: hepatic stellate cells suppress NK cell-sustained breast cancer dormancy. Nature. 2021;600:E7","journal-title":"Nature."},{"key":"10838_CR16","doi-asserted-by":"publisher","first-page":"G234","DOI":"10.1152\/ajpgi.00254.2021","volume":"322","author":"E Kostallari","year":"2022","unstructured":"Kostallari E, Wei B, Sicard D, Li J, Cooper SA, Gao J, et al. Stiffness is associated with hepatic stellate cell heterogeneity during liver fibrosis. Am J Physiol Gastrointest Liver Physiol. 2022;322:G234\u2013G246","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10838_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1002147","volume":"7","author":"KKY Lai","year":"2011","unstructured":"Lai KKY, Shang S, Lohia N, Booth GC, Masse DJ, Fausto N, et al. Extracellular matrix dynamics in hepatocarcinogenesis: a comparative proteomics study of PDGFC transgenic and Pten null mouse models. PLoS Genet. 2011;7: e1002147","journal-title":"PLoS Genet"},{"key":"10838_CR18","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/s41556-023-01092-1","volume":"25","author":"B Wu","year":"2023","unstructured":"Wu B, Liu D-A, Guan L, Myint PK, Chin L, Dang H, et al. Stiff matrix induces exosome secretion to promote tumour growth. Nat Cell Biol. 2023;25:415\u2013424","journal-title":"Nat Cell Biol"},{"key":"10838_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2019.113771","volume":"172","author":"P-C Zhang","year":"2020","unstructured":"Zhang P-C, Liu X, Li M-M, Ma Y-Y, Sun H-T, Tian X-Y, et al. AT-533, a novel Hsp90 inhibitor, inhibits breast cancer growth and HIF-1\u03b1\/VEGF\/VEGFR-2-mediated angiogenesis in vitro and in vivo. Biochem Pharmacol. 2020;172: 113771","journal-title":"Biochem Pharmacol"},{"key":"10838_CR20","doi-asserted-by":"publisher","DOI":"10.2174\/0118761429266116231123160809","volume":"17","author":"C-L Yin","year":"2024","unstructured":"Yin C-L, Ma Y-J. The regulatory mechanism of hypoxia-inducible factor 1 and its clinical significance. Curr Mol Pharmacol. 2024;17: e18761429266116","journal-title":"Curr Mol Pharmacol"},{"key":"10838_CR21","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12943-024-01972-6","volume":"23","author":"S Peng","year":"2024","unstructured":"Peng S, Lin A, Jiang A, Zhang C, Zhang J, Cheng Q, et al. CTLs heterogeneity and plasticity: implications for cancer immunotherapy. Mol Cancer. 2024;23:58","journal-title":"Mol Cancer"},{"key":"10838_CR22","doi-asserted-by":"publisher","first-page":"4436","DOI":"10.3748\/wjg.v24.i39.4436","volume":"24","author":"JM O\u2019Rourke","year":"2018","unstructured":"O\u2019Rourke JM, Sagar VM, Shah T, Shetty S. Carcinogenesis on the background of liver fibrosis: implications for the management of hepatocellular cancer. World J Gastroenterol. 2018;24:4436\u20134447","journal-title":"World J Gastroenterol"},{"key":"10838_CR23","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000342","volume":"8","author":"M Li","year":"2024","unstructured":"Li M, Huang F, Zhu W, Peng Y, Xu F, Li W, et al. Dynamic regulation of EXO1 promotes the progression from liver fibrosis to HCC through TGF-\u03b21\/Smad signaling feedback loop. Hepatol Commun. 2024;8: e0342","journal-title":"Hepatol Commun"},{"key":"10838_CR24","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/nature02924","volume":"431","author":"E Pikarsky","year":"2004","unstructured":"Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature. 2004;431:461\u2013466","journal-title":"Nature"},{"key":"10838_CR25","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1159\/000343852","volume":"2","author":"G Ramakrishna","year":"2013","unstructured":"Ramakrishna G, Rastogi A, Trehanpati N, Sen B, Khosla R, Sarin SK. From cirrhosis to hepatocellular carcinoma: new molecular insights on inflammation and cellular senescence. Liver Cancer. 2013;2:367\u2013383","journal-title":"Liver Cancer"},{"key":"10838_CR26","doi-asserted-by":"publisher","first-page":"4430","DOI":"10.7150\/thno.85369","volume":"13","author":"Y Zhou","year":"2023","unstructured":"Zhou Y, Zhang L, Ma Y, Xie L, Yang Y-Y, Jin C, et al. Secretome of senescent hepatic stellate cells favors malignant transformation from nonalcoholic steatohepatitis-fibrotic progression to hepatocellular carcinoma. Theranostics. 2023;13:4430\u20134448","journal-title":"Theranostics"},{"key":"10838_CR27","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12876-024-03149-3","volume":"24","author":"S Kurokawa","year":"2024","unstructured":"Kurokawa S, Kobori T, Yoneda M, Ogawa Y, Honda Y, Kessoku T, et al. Identification of differentially methylated regions associated with both liver fibrosis and hepatocellular carcinoma. BMC Gastroenterol. 2024;24:57","journal-title":"BMC Gastroenterol"},{"key":"10838_CR28","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nrd.2016.246","volume":"16","author":"R Rupaimoole","year":"2017","unstructured":"Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017;16:203\u2013222","journal-title":"Nat Rev Drug Discov"},{"key":"10838_CR29","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.addr.2017.10.011","volume":"121","author":"CL Wilson","year":"2017","unstructured":"Wilson CL, Mann DA, Borthwick LA. Epigenetic reprogramming in liver fibrosis and cancer. Adv Drug Deliv Rev. 2017;121:124\u2013132","journal-title":"Adv Drug Deliv Rev"},{"key":"10838_CR30","doi-asserted-by":"publisher","first-page":"1196298","DOI":"10.3389\/fonc.2023.1196298","volume":"13","author":"L Shan","year":"2023","unstructured":"Shan L, Wang F, Xue W, Zhai D, Liu J, Lv X. New insights into fibrotic signaling in hepatocellular carcinoma. Front Oncol. 2023;13:1196298","journal-title":"Front Oncol"},{"key":"10838_CR31","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1002\/mc.22851","volume":"57","author":"J Gao","year":"2018","unstructured":"Gao J, Wang Z, Wang G-J, Gao N, Li J, Zhang Y-F, et al. From hepatofibrosis to hepatocarcinogenesis: higher cytochrome P450 2E1 activity is a potential risk factor. Mol Carcinog. 2018;57:1371\u20131382","journal-title":"Mol Carcinog"},{"key":"10838_CR32","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.14102","author":"Y Imaoka","year":"2024","unstructured":"Imaoka Y, Ohira M, Imaoka K, Bekki T, Nakano R, Yano T, et al. Interleukin-33 and liver natural killer cells: a novel perspective on antitumor activity in liver fibrosis. Hepatol Res Off J Jpn Soc Hepatol. 2024. https:\/\/doi.org\/10.1111\/hepr.14102","journal-title":"Hepatol Res Off J Jpn Soc Hepatol."},{"key":"10838_CR33","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13045-024-01634-6","volume":"18","author":"A Glaviano","year":"2025","unstructured":"Glaviano A, Lau HS-H, Carter LM, Lee EHC, Lam HY, Okina E, et al. Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition. J Hematol Oncol J Hematol Oncol. 2025;18:6","journal-title":"J Hematol Oncol J Hematol Oncol"},{"key":"10838_CR34","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.jhep.2019.08.019","volume":"71","author":"M Serra-Burriel","year":"2019","unstructured":"Serra-Burriel M, Graupera I, Tor\u00e1n P, Thiele M, Roulot D, Wai-Sun Wong V, et al. Transient elastography for screening of liver fibrosis: cost-effectiveness analysis from six prospective cohorts in Europe and Asia. J Hepatol. 2019;71:1141\u20131151","journal-title":"J Hepatol"},{"key":"10838_CR35","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1002\/hep.30979","volume":"71","author":"L Asphaug","year":"2020","unstructured":"Asphaug L, Thiele M, Krag A, Melberg HO. Cost-effectiveness of noninvasive screening for alcohol-related liver fibrosis. Hepatol Baltim Md. 2020;71:2093\u20132104","journal-title":"Hepatol Baltim Md"},{"key":"10838_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.tice.2024.102559","volume":"91","author":"Z Sun","year":"2024","unstructured":"Sun Z, Chen G. Impact of heterogeneity in liver matrix and intrahepatic cells on the progression of hepatic fibrosis. Tissue Cell. 2024;91: 102559","journal-title":"Tissue Cell"},{"key":"10838_CR37","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1038\/s41417-024-00764-w","volume":"31","author":"F Safri","year":"2024","unstructured":"Safri F, Nguyen R, Zerehpooshnesfchi S, George J, Qiao L. Heterogeneity of hepatocellular carcinoma: from mechanisms to clinical implications. Cancer Gene Ther. 2024;31:1105\u20131112","journal-title":"Cancer Gene Ther"},{"key":"10838_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114448","volume":"188","author":"N Li","year":"2022","unstructured":"Li N, Zhang X, Zhou J, Li W, Shu X, Wu Y, et al. Multiscale biomechanics and mechanotransduction from liver fibrosis to cancer. Adv Drug Deliv Rev. 2022;188: 114448","journal-title":"Adv Drug Deliv Rev"},{"key":"10838_CR39","doi-asserted-by":"publisher","first-page":"5239","DOI":"10.7150\/ijbs.102706","volume":"20","author":"J Hong","year":"2024","unstructured":"Hong J, Yu J, Buratto D, Chen W, Zhou R, Ling S, et al. Unveiling the role of mechanical microenvironment in hepatocellular carcinoma: molecular mechanisms and implications for therapeutic strategies. Int J Biol Sci. 2024;20:5239\u20135253","journal-title":"Int J Biol Sci"},{"key":"10838_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2023.113878","volume":"434","author":"S Verma","year":"2024","unstructured":"Verma S, Ishteyaque S, Washimkar KR, Verma S, Nilakanth MM. Mitochondrial-mediated nuclear remodeling and macrophage polarizations: a key switch from liver fibrosis to HCC progression. Exp Cell Res. 2024;434: 113878","journal-title":"Exp Cell Res"},{"key":"10838_CR41","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1146\/annurev-pathol-052016-100322","volume":"12","author":"S Affo","year":"2017","unstructured":"Affo S, Yu L-X, Schwabe RF. The role of cancer-associated fibroblasts and fibrosis in liver cancer. Annu Rev Pathol. 2017;12:153\u2013186","journal-title":"Annu Rev Pathol"},{"key":"10838_CR42","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1146\/annurev-pathol-011110-130246","volume":"6","author":"V Hernandez-Gea","year":"2011","unstructured":"Hernandez-Gea V, Friedman SL. Pathogenesis of liver fibrosis. Annu Rev Pathol. 2011;6:425\u2013456","journal-title":"Annu Rev Pathol"},{"key":"10838_CR43","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1172\/JCI24282","volume":"115","author":"R Bataller","year":"2005","unstructured":"Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005;115:209\u2013218","journal-title":"J Clin Invest"},{"key":"10838_CR44","doi-asserted-by":"publisher","first-page":"d69","DOI":"10.2741\/887","volume":"8","author":"E G\u00e4bele","year":"2003","unstructured":"G\u00e4bele E, Brenner DA, Rippe RA. Liver fibrosis: signals leading to the amplification of the fibrogenic hepatic stellate cell. Front Biosci J Virtual Libr. 2003;8:d69-77","journal-title":"Front Biosci J Virtual Libr"},{"key":"10838_CR45","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1055\/s-0040-1708876","volume":"40","author":"M Matsuda","year":"2020","unstructured":"Matsuda M, Seki E. Hepatic stellate cell-macrophage crosstalk in liver fibrosis and carcinogenesis. Semin Liver Dis. 2020;40:307\u2013320","journal-title":"Semin Liver Dis"},{"key":"10838_CR46","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41419-023-06077-4","volume":"14","author":"J Otto","year":"2023","unstructured":"Otto J, Verwaayen A, Penners C, Hundertmark J, Lin C, Kallen C, et al. Expression of cyclin E1 in hepatic stellate cells is critical for the induction and progression of liver fibrosis and hepatocellular carcinoma in mice. Cell Death Dis. 2023;14:549","journal-title":"Cell Death Dis"},{"key":"10838_CR47","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/hepr.12356","volume":"45","author":"N Lin","year":"2015","unstructured":"Lin N, Chen Z, Lu Y, Li Y, Hu K, Xu R. Role of activated hepatic stellate cells in proliferation and metastasis of hepatocellular carcinoma. Hepatol Res Off J Jpn Soc Hepatol. 2015;45:326\u2013336","journal-title":"Hepatol Res Off J Jpn Soc Hepatol"},{"key":"10838_CR48","first-page":"13369","volume":"42","author":"S Aleffi","year":"2015","unstructured":"Aleffi S, Petrai I, Bertolani C, Parola M, Colombatto S, Novo E, et al. Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells\u2020. Hepatology. 2005;42:1339","journal-title":"Hepatology"},{"key":"10838_CR49","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1053\/j.gastro.2008.07.065","volume":"135","author":"K Taura","year":"2008","unstructured":"Taura K, De Minicis S, Seki E, Hatano E, Iwaisako K, Osterreicher CH, et al. Hepatic stellate cells secrete angiopoietin 1 that induces angiogenesis in liver fibrosis. Gastroenterology. 2008;135:1729\u20131738","journal-title":"Gastroenterology"},{"key":"10838_CR50","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.cytogfr.2005.04.007","volume":"16","author":"RM Strieter","year":"2005","unstructured":"Strieter RM, Burdick MD, Gomperts BN, Belperio JA, Keane MP. CXC chemokines in angiogenesis. Cytokine Growth Factor Rev. 2005;16:593\u2013609","journal-title":"Cytokine Growth Factor Rev"},{"key":"10838_CR51","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.bbadis.2012.11.004","volume":"1832","author":"H Sahin","year":"2013","unstructured":"Sahin H, Wasmuth HE. Chemokines in tissue fibrosis. Biochim Biophys Acta. 2013;1832:1041\u20131048","journal-title":"Biochim Biophys Acta"},{"issue":"293","key":"10838_CR52","first-page":"1492","volume":"2010","author":"B-B Wang","year":"2007","unstructured":"Wang B-B, Cheng J-Y, Gao H-H, Zhang Y, Chen Z-N, Bian H. Hepatic stellate cells in inflammation-fibrosis-carcinoma axis. Anat Rec Hoboken NJ. 2007;2010(293):1492\u20131496","journal-title":"Anat Rec Hoboken NJ"},{"key":"10838_CR53","first-page":"5254","volume":"13","author":"C Sun","year":"2023","unstructured":"Sun C, Xu W, Xia Y, Wang S. PRDM16 from hepatic stellate cells-derived extracellular vesicles promotes hepatocellular carcinoma progression. Am J Cancer Res. 2023;13:5254\u20135270","journal-title":"Am J Cancer Res"},{"key":"10838_CR54","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1038\/s41571-021-00546-5","volume":"18","author":"Y Chen","year":"2021","unstructured":"Chen Y, McAndrews KM, Kalluri R. Clinical and therapeutic relevance of cancer-associated fibroblasts. Nat Rev Clin Oncol. 2021;18:792\u2013804","journal-title":"Nat Rev Clin Oncol"},{"key":"10838_CR55","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12943-023-01722-0","volume":"22","author":"Z Gao","year":"2023","unstructured":"Gao Z, Bai Y, Lin A, Jiang A, Zhou C, Cheng Q, et al. Gamma delta T-cell-based immune checkpoint therapy: attractive candidate for antitumor treatment. Mol Cancer. 2023;22:31","journal-title":"Mol Cancer"},{"key":"10838_CR56","first-page":"324","volume":"37","author":"Y Zhou","year":"2018","unstructured":"Zhou Y, Ren H, Dai B, Li J, Shang L, Huang J, et al. Hepatocellular carcinoma-derived exosomal miRNA-21 contributes to tumor progression by converting hepatocyte stellate cells to cancer-associated fibroblasts. J Exp Clin Cancer Res CR. 2018;37:324","journal-title":"J Exp Clin Cancer Res CR"},{"key":"10838_CR57","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000491","volume":"8","author":"A Guillot","year":"2024","unstructured":"Guillot A, Tacke F. Liver macrophages revisited: the expanding universe of versatile responses in a spatiotemporal context. Hepatol Commun. 2024;8: e0491","journal-title":"Hepatol Commun"},{"key":"10838_CR58","doi-asserted-by":"publisher","first-page":"994480","DOI":"10.3389\/fimmu.2022.994480","volume":"13","author":"M Flores Molina","year":"2022","unstructured":"Flores Molina M, Abdelnabi MN, Mazouz S, Villafranca-Baughman D, Trinh VQ-H, Muhammad S, et al. Distinct spatial distribution and roles of Kupffer cells and monocyte-derived macrophages in mouse acute liver injury. Front Immunol. 2022;13:994480","journal-title":"Front Immunol"},{"key":"10838_CR59","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s00432-017-2364-z","volume":"143","author":"Y-F Ding","year":"2017","unstructured":"Ding Y-F, Wu Z-H, Wei Y-J, Shu L, Peng Y-R. Hepatic inflammation-fibrosis-cancer axis in the rat hepatocellular carcinoma induced by diethylnitrosamine. J Cancer Res Clin Oncol. 2017;143:821\u2013834","journal-title":"J Cancer Res Clin Oncol"},{"key":"10838_CR60","doi-asserted-by":"crossref","unstructured":"Yoon SR, Ekihiro S. Toll-like receptors in alcoholic liver disease, non-alcoholic steatohepatitis and carcinogenesis. J Gastroenterol Hepatol. 2013;28 Suppl 1. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/23855294\/. [cited 2024 Nov 30]","DOI":"10.1111\/jgh.12019"},{"key":"10838_CR61","doi-asserted-by":"publisher","first-page":"162","DOI":"10.4254\/wjh.v8.i3.162","volume":"8","author":"JAG Lopes","year":"2016","unstructured":"Lopes JAG, Borges-Canha M, Pimentel-Nunes P. Innate immunity and hepatocarcinoma: can toll-like receptors open the door to oncogenesis? World J Hepatol. 2016;8:162\u2013182","journal-title":"World J Hepatol"},{"key":"10838_CR62","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1136\/gut.2008.156307","volume":"58","author":"A Mencin","year":"2009","unstructured":"Mencin A, Kluwe J, Schwabe RF. Toll-like receptors as targets in chronic liver diseases. Gut. 2009;58:704\u2013720","journal-title":"Gut"},{"key":"10838_CR63","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.667875","volume":"12","author":"A Lin","year":"2021","unstructured":"Lin A, Zhang H, Meng H, Deng Z, Gu T, Luo P, et al. TNF-alpha pathway alternation predicts survival of immune checkpoint inhibitors in non-small cell lung cancer. Front Immunol. 2021;12: 667875","journal-title":"Front Immunol"},{"key":"10838_CR64","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.756722","volume":"12","author":"Q Yang","year":"2021","unstructured":"Yang Q, Zhang H, Wei T, Lin A, Sun Y, Luo P, et al. Single-cell RNA sequencing reveals the heterogeneity of tumor-associated macrophage in non-small cell lung cancer and differences between sexes. Front Immunol. 2021;12: 756722","journal-title":"Front Immunol"},{"key":"10838_CR65","volume":"17","author":"SM Manohar","year":"2024","unstructured":"Manohar SM. At the crossroads of TNF \u03b1 signaling and cancer. Curr Mol Pharmacol. 2024;17: e060923220758","journal-title":"Curr Mol Pharmacol"},{"key":"10838_CR66","doi-asserted-by":"publisher","DOI":"10.2174\/0118761429310703240823045808","volume":"17","author":"B Sensi","year":"2024","unstructured":"Sensi B, Angelico R, Toti L, Conte L, Coppola A, Tisone G, et al. Mechanism, potential, and concerns of immunotherapy for hepatocellular carcinoma and liver transplantation. Curr Mol Pharmacol. 2024;17: e18761429310703","journal-title":"Curr Mol Pharmacol"},{"key":"10838_CR67","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1177\/1535370219898141","volume":"245","author":"D Dhar","year":"2020","unstructured":"Dhar D, Baglieri J, Kisseleva T, Brenner DA. Mechanisms of liver fibrosis and its role in liver cancer. Exp Biol Med Maywood NJ. 2020;245:96\u2013108","journal-title":"Exp Biol Med Maywood NJ"},{"key":"10838_CR68","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.jhep.2016.04.018","volume":"65","author":"G Marrone","year":"2016","unstructured":"Marrone G, Shah VH, Gracia-Sancho J. Sinusoidal communication in liver fibrosis and regeneration. J Hepatol. 2016;65:608\u2013617","journal-title":"J Hepatol"},{"key":"10838_CR69","first-page":"598","volume":"54","author":"H Li","year":"2022","unstructured":"Li H. Intercellular crosstalk of liver sinusoidal endothelial cells in liver fibrosis, cirrhosis and hepatocellular carcinoma. Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver. 2022;54:598\u2013613","journal-title":"Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver"},{"key":"10838_CR70","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1080\/17474124.2021.1842732","volume":"15","author":"H Li","year":"2021","unstructured":"Li H. Angiogenesis in the progression from liver fibrosis to cirrhosis and hepatocelluar carcinoma. Expert Rev Gastroenterol Hepatol. 2021;15:217\u2013233","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10838_CR71","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1016\/j.cell.2019.07.021","volume":"178","author":"M Xu","year":"2019","unstructured":"Xu M, Xu H-H, Lin Y, Sun X, Wang L-J, Fang Z-P, et al. LECT2, a ligand for Tie1, plays a crucial role in liver fibrogenesis. Cell. 2019;178:1478-1492.e20","journal-title":"Cell"},{"key":"10838_CR72","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/hep.31183","volume":"72","author":"T Su","year":"2020","unstructured":"Su T, Iwakiri Y. Endothelial leukocyte cell-derived chemotaxin 2\/Tyrosine kinase with immunoglobulin-like and epidermal growth factor-like domains 1 signaling in liver fibrosis. Hepatol Baltim Md. 2020;72:347\u2013349","journal-title":"Hepatol Baltim Md"},{"key":"10838_CR73","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jhep.2012.08.026","volume":"58","author":"G Marrone","year":"2013","unstructured":"Marrone G, Russo L, Rosado E, Hide D, Garc\u00eda-Carde\u00f1a G, Garc\u00eda-Pag\u00e1n JC, et al. The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial-stellate cell deactivation induced by statins. J Hepatol. 2013;58:98\u2013103","journal-title":"J Hepatol"},{"key":"10838_CR74","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1083\/jcb.127.6.2037","volume":"127","author":"WR Jarnagin","year":"1994","unstructured":"Jarnagin WR, Rockey DC, Koteliansky VE, Wang SS, Bissell DM. Expression of variant fibronectins in wound healing: cellular source and biological activity of the EIIIA segment in rat hepatic fibrogenesis. J Cell Biol. 1994;127:2037\u20132048","journal-title":"J Cell Biol"},{"key":"10838_CR75","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1002\/hep.27376","volume":"61","author":"LD DeLeve","year":"2015","unstructured":"DeLeve LD. Liver sinusoidal endothelial cells in hepatic fibrosis. Hepatol Baltim Md. 2015;61:1740\u20131746","journal-title":"Hepatol Baltim Md"},{"key":"10838_CR76","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1002\/hep.22351","volume":"48","author":"LD Deleve","year":"2008","unstructured":"Deleve LD, Wang X, Guo Y. Sinusoidal endothelial cells prevent rat stellate cell activation and promote reversion to quiescence. Hepatol Baltim Md. 2008;48:920\u2013930","journal-title":"Hepatol Baltim Md"},{"key":"10838_CR77","doi-asserted-by":"publisher","first-page":"2917","DOI":"10.3390\/ijms19102917","volume":"19","author":"D Overi","year":"2018","unstructured":"Overi D, Carpino G, Cardinale V, Franchitto A, Safarikia S, Onori P, et al. Contribution of resident stem cells to liver and biliary tree regeneration in human diseases. Int J Mol Sci. 2018;19:2917","journal-title":"Int J Mol Sci"},{"key":"10838_CR78","doi-asserted-by":"publisher","first-page":"590","DOI":"10.3390\/cells9030590","volume":"9","author":"D Overi","year":"2020","unstructured":"Overi D, Carpino G, Franchitto A, Onori P, Gaudio E. Hepatocyte injury and hepatic stem cell niche in the progression of non-alcoholic steatohepatitis. Cells. 2020;9:590","journal-title":"Cells"},{"key":"10838_CR79","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1053\/j.gastro.2013.11.034","volume":"146","author":"MJ Williams","year":"2014","unstructured":"Williams MJ, Clouston AD, Forbes SJ. Links between hepatic fibrosis, ductular reaction, and progenitor cell expansion. Gastroenterology. 2014;146:349\u2013356","journal-title":"Gastroenterology"},{"key":"10838_CR80","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1093\/toxsci\/kfs342","volume":"132","author":"T Uehara","year":"2013","unstructured":"Uehara T, Ainslie GR, Kutanzi K, Pogribny IP, Muskhelishvili L, Izawa T, et al. Molecular mechanisms of fibrosis-associated promotion of liver carcinogenesis. Toxicol Sci Off J Soc Toxicol. 2013;132:53\u201363","journal-title":"Toxicol Sci Off J Soc Toxicol"},{"key":"10838_CR81","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.3390\/cells9092027","volume":"9","author":"L Kaps","year":"2020","unstructured":"Kaps L, Schuppan D. Targeting cancer associated fibroblasts in liver fibrosis and liver cancer using nanocarriers. Cells. 2020;9:2027","journal-title":"Cells"},{"key":"10838_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215970","volume":"552","author":"J Xu","year":"2023","unstructured":"Xu J, Zhang L, Li N, Dai J, Zhang R, Yao F, et al. Etomidate elicits anti-tumor capacity by disrupting the JAK2\/STAT3 signaling pathway in hepatocellular carcinoma. Cancer Lett. 2023;552: 215970","journal-title":"Cancer Lett"},{"key":"10838_CR83","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s11658-022-00388-8","volume":"27","author":"Q Xu","year":"2022","unstructured":"Xu Q, Liao Z, Gong Z, Liu X, Yang Y, Wang Z, et al. Down-regulation of EVA1A by miR-103a-3p promotes hepatocellular carcinoma cells proliferation and migration. Cell Mol Biol Lett. 2022;27:93","journal-title":"Cell Mol Biol Lett"},{"key":"10838_CR84","doi-asserted-by":"publisher","first-page":"581","DOI":"10.3390\/ijms20030581","volume":"20","author":"H Moon","year":"2019","unstructured":"Moon H, Cho K, Shin S, Kim DY, Han K-H, Ro SW. High risk of hepatocellular carcinoma development in fibrotic liver: role of the hippo-YAP\/TAZ signaling pathway. Int J Mol Sci. 2019;20:581","journal-title":"Int J Mol Sci"},{"key":"10838_CR85","doi-asserted-by":"publisher","DOI":"10.1111\/cns.14489","volume":"30","author":"W-W Duan","year":"2024","unstructured":"Duan W-W, Yang L-T, Liu J, Dai Z-Y, Wang Z-Y, Zhang H, et al. A TGF-\u03b2 signaling-related lncRNA signature for prediction of glioma prognosis, immune microenvironment, and immunotherapy response. CNS Neurosci Ther. 2024;30: e14489","journal-title":"CNS Neurosci Ther"},{"key":"10838_CR86","doi-asserted-by":"publisher","first-page":"8766448","DOI":"10.1155\/2022\/8766448","volume":"2022","author":"A Lin","year":"2022","unstructured":"Lin A, Zhu L, Jiang A, Mou W, Zhang J, Luo P. Activation of the TGF-\u03b2 pathway enhances the efficacy of platinum-based chemotherapy in small cell lung cancer patients. Dis Markers. 2022;2022:8766448","journal-title":"Dis Markers"},{"key":"10838_CR87","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.16060","volume":"11","author":"X Peng","year":"2023","unstructured":"Peng X, Yang H, Tao L, Xiao J, Zeng Y, Shen Y, et al. Fluorofenidone alleviates liver fibrosis by inhibiting hepatic stellate cell autophagy via the TGF-\u03b21\/Smad pathway: implications for liver cancer. PeerJ. 2023;11: e16060","journal-title":"PeerJ"},{"key":"10838_CR88","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/nri.2017.142","volume":"18","author":"K Taniguchi","year":"2018","unstructured":"Taniguchi K, Karin M. NF-\u03baB, inflammation, immunity and cancer: coming of age. Nat Rev Immunol. 2018;18:309\u2013324","journal-title":"Nat Rev Immunol"},{"key":"10838_CR89","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1158\/1535-7163.MCT-10-0502","volume":"10","author":"L Song","year":"2011","unstructured":"Song L, Rawal B, Nemeth JA, Haura EB. JAK1 activates STAT3 activity in non-small-cell lung cancer cells and IL-6 neutralizing antibodies can suppress JAK1-STAT3 signaling. Mol Cancer Ther. 2011;10:481\u2013494","journal-title":"Mol Cancer Ther"},{"key":"10838_CR90","doi-asserted-by":"publisher","first-page":"HEP18","DOI":"10.2217\/hep-2020-0001","volume":"7","author":"JJ Hin Tang","year":"2020","unstructured":"Hin Tang JJ, Hao Thng DK, Lim JJ, Toh TB. JAK\/STAT signaling in hepatocellular carcinoma. Hepatic Oncol. 2020;7:HEP18","journal-title":"Hepatic Oncol."},{"key":"10838_CR91","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/sj.cr.7290105","volume":"12","author":"W Zhang","year":"2002","unstructured":"Zhang W, Liu HT. MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res. 2002;12:9\u201318","journal-title":"Cell Res"},{"key":"10838_CR92","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.cell.2008.11.017","volume":"136","author":"M Das","year":"2009","unstructured":"Das M, Sabio G, Jiang F, Rinc\u00f3n M, Flavell RA, Davis RJ. Induction of hepatitis by JNK-mediated expression of TNF-alpha. Cell. 2009;136:249\u2013260","journal-title":"Cell"},{"key":"10838_CR93","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1101\/gad.1989311","volume":"25","author":"M Das","year":"2011","unstructured":"Das M, Garlick DS, Greiner DL, Davis RJ. The role of JNK in the development of hepatocellular carcinoma. Genes Dev. 2011;25:634\u2013645","journal-title":"Genes Dev"},{"key":"10838_CR94","first-page":"944","volume":"26","author":"M Calligaris","year":"2021","unstructured":"Calligaris M, Cuffaro D, Bonelli S, Span\u00f2 DP, Rossello A, Nuti E, et al. Strategies to target ADAM17 in disease: from its discovery to the iRhom revolution. Mol Basel Switz. 2021;26:944","journal-title":"Mol Basel Switz"},{"key":"10838_CR95","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2020.06.010","volume":"21","author":"J Zhao","year":"2021","unstructured":"Zhao J, Qi Y-F, Yu Y-R. STAT3: A key regulator in liver fibrosis. Ann Hepatol. 2021;21: 100224","journal-title":"Ann Hepatol"},{"key":"10838_CR96","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.jhep.2022.05.018","volume":"77","author":"L Molina","year":"2022","unstructured":"Molina L, Zhu J, Tr\u00e9po E, Bayard Q, Amaddeo G, GENTHEP Consortium, et al. Bi-allelic hydroxymethylbilane synthase inactivation defines a homogenous clinico-molecular subtype of hepatocellular carcinoma. J Hepatol. 2022;77:1038\u201346","journal-title":"J Hepatol"},{"key":"10838_CR97","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.lfs.2018.10.051","volume":"215","author":"Z Yan","year":"2018","unstructured":"Yan Z, Miao X, Zhang B, Xie J. p53 as a double-edged sword in the progression of non-alcoholic fatty liver disease. Life Sci. 2018;215:64\u201372","journal-title":"Life Sci"},{"key":"10838_CR98","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.676","volume":"5","author":"A Jiang","year":"2024","unstructured":"Jiang A, Li J, He Z, Liu Y, Qiao K, Fang Y, et al. Renal cancer: signaling pathways and advances in targeted therapies. MedComm. 2024;5: e676","journal-title":"MedComm"},{"key":"10838_CR99","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41392-023-01559-5","volume":"8","author":"J Jing","year":"2023","unstructured":"Jing J, Wu Z, Wang J, Luo G, Lin H, Fan Y, et al. Hedgehog signaling in tissue homeostasis, cancers, and targeted therapies. Signal Transduct Target Ther. 2023;8:315","journal-title":"Signal Transduct Target Ther"},{"key":"10838_CR100","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41392-021-00762-6","volume":"7","author":"J Liu","year":"2022","unstructured":"Liu J, Xiao Q, Xiao J, Niu C, Li Y, Zhang X, et al. Wnt\/\u03b2-catenin signalling: function, biological mechanisms, and therapeutic opportunities. Signal Transduct Target Ther. 2022;7:3","journal-title":"Signal Transduct Target Ther"},{"key":"10838_CR101","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41419-021-03494-1","volume":"12","author":"Y Xia","year":"2021","unstructured":"Xia Y, Zhen L, Li H, Wang S, Chen S, Wang C, et al. MIRLET7BHG promotes hepatocellular carcinoma progression by activating hepatic stellate cells through exosomal SMO to trigger Hedgehog pathway. Cell Death Dis. 2021;12:326","journal-title":"Cell Death Dis"},{"key":"10838_CR102","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/s41392-022-01191-9","volume":"7","author":"M Fu","year":"2022","unstructured":"Fu M, Hu Y, Lan T, Guan K-L, Luo T, Luo M. The Hippo signalling pathway and its implications in human health and diseases. Signal Transduct Target Ther. 2022;7:376","journal-title":"Signal Transduct Target Ther"},{"key":"10838_CR103","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/path.5756","volume":"255","author":"H Xiao","year":"2021","unstructured":"Xiao H, Zhang Y, Li Z, Liu B, Cui D, Liu F, et al. Periostin deficiency reduces diethylnitrosamine-induced liver cancer in mice by decreasing hepatic stellate cell activation and cancer cell proliferation. J Pathol. 2021;255:212\u2013223","journal-title":"J Pathol"},{"key":"10838_CR104","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1471-2121-6-8","volume":"6","author":"S Rahman","year":"2005","unstructured":"Rahman S, Patel Y, Murray J, Patel KV, Sumathipala R, Sobel M, et al. Novel hepatocyte growth factor (HGF) binding domains on fibronectin and vitronectin coordinate a distinct and amplified Met-integrin induced signalling pathway in endothelial cells. BMC Cell Biol. 2005;6:8","journal-title":"BMC Cell Biol"},{"key":"10838_CR105","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41419-020-2372-9","volume":"11","author":"T Xu","year":"2020","unstructured":"Xu T, Lu Z, Xiao Z, Liu F, Chen Y, Wang Z, et al. Myofibroblast induces hepatocyte-to-ductal metaplasia via laminin-\u0251v\u03b26 integrin in liver fibrosis. Cell Death Dis. 2020;11:199","journal-title":"Cell Death Dis"},{"key":"10838_CR106","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1002\/jcb.27681","volume":"120","author":"M Najafi","year":"2019","unstructured":"Najafi M, Farhood B, Mortezaee K. Extracellular matrix (ECM) stiffness and degradation as cancer drivers. J Cell Biochem. 2019;120:2782\u20132790","journal-title":"J Cell Biochem"},{"key":"10838_CR107","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12943-023-01744-8","volume":"22","author":"Z Yuan","year":"2023","unstructured":"Yuan Z, Li Y, Zhang S, Wang X, Dou H, Yu X, et al. Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments. Mol Cancer. 2023;22:48","journal-title":"Mol Cancer"},{"key":"10838_CR108","doi-asserted-by":"publisher","first-page":"787","DOI":"10.3389\/fonc.2020.00787","volume":"10","author":"EJ Hoffmann","year":"2020","unstructured":"Hoffmann EJ, Ponik SM. Biomechanical contributions to macrophage activation in the tumor microenvironment. Front Oncol. 2020;10:787","journal-title":"Front Oncol"},{"key":"10838_CR109","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.3390\/ijms20071745","volume":"20","author":"A Sircana","year":"2019","unstructured":"Sircana A, Paschetta E, Saba F, Molinaro F, Musso G. Recent insight into the role of fibrosis in nonalcoholic steatohepatitis-related hepatocellular carcinoma. Int J Mol Sci. 2019;20:1745","journal-title":"Int J Mol Sci"},{"key":"10838_CR110","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.3390\/ijms20071723","volume":"20","author":"J Baglieri","year":"2019","unstructured":"Baglieri J, Brenner DA, Kisseleva T. The role of fibrosis and liver-associated fibroblasts in the pathogenesis of hepatocellular carcinoma. Int J Mol Sci. 2019;20:1723","journal-title":"Int J Mol Sci"},{"key":"10838_CR111","doi-asserted-by":"publisher","first-page":"1277808","DOI":"10.3389\/fimmu.2023.1277808","volume":"14","author":"M Casari","year":"2023","unstructured":"Casari M, Siegl D, Deppermann C, Schuppan D. Macrophages and platelets in liver fibrosis and hepatocellular carcinoma. Front Immunol. 2023;14:1277808","journal-title":"Front Immunol"},{"key":"10838_CR112","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.lfs.2019.04.021","volume":"226","author":"Y Jia","year":"2019","unstructured":"Jia Y, Zhong F, Jiang S, Guo Q, Jin H, Wang F, et al. Periostin in chronic liver diseases: current research and future perspectives. Life Sci. 2019;226:91\u201397","journal-title":"Life Sci"},{"key":"10838_CR113","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioadv.2023.213289","volume":"146","author":"GS van Tienderen","year":"2023","unstructured":"van Tienderen GS, Conboy J, Muntz I, Willemse J, Tieleman J, Monfils K, et al. Tumor decellularization reveals proteomic and mechanical characteristics of the extracellular matrix of primary liver cancer. Biomater Adv. 2023;146: 213289","journal-title":"Biomater Adv"},{"key":"10838_CR114","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.7150\/ijbs.82177","volume":"19","author":"J Cai","year":"2023","unstructured":"Cai J, Chen T, Jiang Z, Yan J, Ye Z, Ruan Y, et al. Bulk and single-cell transcriptome profiling reveal extracellular matrix mechanical regulation of lipid metabolism reprograming through YAP\/TEAD4\/ACADL axis in hepatocellular carcinoma. Int J Biol Sci. 2023;19:2114\u20132131","journal-title":"Int J Biol Sci"},{"key":"10838_CR115","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1016\/j.celrep.2014.08.028","volume":"8","author":"D Huang","year":"2014","unstructured":"Huang D, Li T, Li X, Zhang L, Sun L, He X, et al. HIF-1-mediated suppression of acyl-CoA dehydrogenases and fatty acid oxidation is critical for cancer progression. Cell Rep. 2014;8:1930\u20131942","journal-title":"Cell Rep"},{"key":"10838_CR116","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1002\/ijc.34332","volume":"152","author":"T Gu","year":"2023","unstructured":"Gu T, Jiang A, Zhou C, Lin A, Cheng Q, Liu Z, et al. Adverse reactions associated with immune checkpoint inhibitors and bevacizumab: a pharmacovigilance analysis. Int J Cancer. 2023;152:480\u2013495","journal-title":"Int J Cancer"},{"key":"10838_CR117","doi-asserted-by":"publisher","first-page":"1488853","DOI":"10.3389\/fimmu.2024.1488853","volume":"15","author":"H Kuang","year":"2024","unstructured":"Kuang H, Yan Q, Li Z, Lin A, Li K, Zhang J, et al. Comprehensive analysis of VEGF\/VEGFR inhibitor-induced immune-mediated hypertension: integrating pharmacovigilance, clinical data, and preclinical models. Front Immunol. 2024;15:1488853","journal-title":"Front Immunol"},{"key":"10838_CR118","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1016\/j.drudis.2021.07.024","volume":"26","author":"K Wang","year":"2021","unstructured":"Wang K, Chen Q, Liu N, Zhang J, Pan X. Recent advances in, and challenges of, anti-angiogenesis agents for tumor chemotherapy based on vascular normalization. Drug Discov Today. 2021;26:2743\u20132753","journal-title":"Drug Discov Today"},{"key":"10838_CR119","doi-asserted-by":"publisher","first-page":"308","DOI":"10.3389\/fphys.2013.00308","volume":"4","author":"C Chaussain","year":"2013","unstructured":"Chaussain C, Boukpessi T, Khaddam M, Tjaderhane L, George A, Menashi S. Dentin matrix degradation by host matrix metalloproteinases: inhibition and clinical perspectives toward regeneration. Front Physiol. 2013;4:308","journal-title":"Front Physiol"},{"key":"10838_CR120","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/1471-2407-6-89","volume":"6","author":"S Di Gioia","year":"2006","unstructured":"Di Gioia S, Bianchi P, Destro A, Grizzi F, Malesci A, Laghi L, et al. Quantitative evaluation of RASSF1A methylation in the non-lesional, regenerative and neoplastic liver. BMC Cancer. 2006;6:89","journal-title":"BMC Cancer"},{"key":"10838_CR121","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.jhep.2010.08.021","volume":"54","author":"T-H Um","year":"2011","unstructured":"Um T-H, Kim H, Oh B-K, Kim MS, Kim KS, Jung G, et al. Aberrant CpG island hypermethylation in dysplastic nodules and early HCC of hepatitis B virus-related human multistep hepatocarcinogenesis. J Hepatol. 2011;54:939\u2013947","journal-title":"J Hepatol"},{"key":"10838_CR122","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1002\/mc.1022","volume":"30","author":"TJ Park","year":"2001","unstructured":"Park TJ, Kim HS, Byun KH, Jang JJ, Lee YS, Lim IK. Sequential changes in hepatocarcinogenesis induced by diethylnitrosamine plus thioacetamide in Fischer 344 rats: induction of gankyrin expression in liver fibrosis, pRB degradation in cirrhosis, and methylation of p16(INK4A) exon 1 in hepatocellular carcinoma. Mol Carcinog. 2001;30:138\u2013150","journal-title":"Mol Carcinog"},{"key":"10838_CR123","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1016\/j.cmet.2023.06.013","volume":"35","author":"H Rho","year":"2023","unstructured":"Rho H, Terry AR, Chronis C, Hay N. Hexokinase 2-mediated gene expression via histone lactylation is required for hepatic stellate cell activation and liver fibrosis. Cell Metab. 2023;35:1406-1423.e8","journal-title":"Cell Metab"},{"key":"10838_CR124","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1002\/ijc.25920","volume":"129","author":"W Zhao","year":"2011","unstructured":"Zhao W, Zhang L, Yin Z, Su W, Ren G, Zhou C, et al. Activated hepatic stellate cells promote hepatocellular carcinoma development in immunocompetent mice. Int J Cancer. 2011;129:2651\u20132661","journal-title":"Int J Cancer"},{"key":"10838_CR125","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1002\/hep.20488","volume":"40","author":"M-C Yu","year":"2004","unstructured":"Yu M-C, Chen C-H, Liang X, Wang L, Gandhi CR, Fung JJ, et al. Inhibition of T-cell responses by hepatic stellate cells via B7-H1-mediated T-cell apoptosis in mice. Hepatol Baltim Md. 2004;40:1312\u20131321","journal-title":"Hepatol Baltim Md"},{"key":"10838_CR126","doi-asserted-by":"publisher","first-page":"457","DOI":"10.3892\/ijo.2012.1497","volume":"41","author":"W Zhao","year":"2012","unstructured":"Zhao W, Su W, Kuang P, Zhang L, Liu J, Yin Z, et al. The role of hepatic stellate cells in the regulation of T-cell function and the promotion of hepatocellular carcinoma. Int J Oncol. 2012;41:457\u2013464","journal-title":"Int J Oncol"},{"key":"10838_CR127","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1186\/s12967-024-05104-y","volume":"22","author":"Y Li","year":"2024","unstructured":"Li Y, Zhang C, Jiang A, Lin A, Liu Z, Cheng X, et al. Potential anti-tumor effects of regulatory T cells in the tumor microenvironment: a review. J Transl Med. 2024;22:293","journal-title":"J Transl Med"},{"key":"10838_CR128","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/labinvest.2013.139","volume":"94","author":"W Zhao","year":"2014","unstructured":"Zhao W, Zhang L, Xu Y, Zhang Z, Ren G, Tang K, et al. Hepatic stellate cells promote tumor progression by enhancement of immunosuppressive cells in an orthotopic liver tumor mouse model. Lab Investig J Tech Methods Pathol. 2014;94:182\u2013191","journal-title":"Lab Investig J Tech Methods Pathol"},{"key":"10838_CR129","doi-asserted-by":"publisher","first-page":"8866","DOI":"10.18632\/oncotarget.6839","volume":"7","author":"Y Xu","year":"2016","unstructured":"Xu Y, Zhao W, Xu J, Li J, Hong Z, Yin Z, et al. Activated hepatic stellate cells promote liver cancer by induction of myeloid-derived suppressor cells through cyclooxygenase-2. Oncotarget. 2016;7:8866\u20138878","journal-title":"Oncotarget"},{"key":"10838_CR130","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1002\/hep.27822","volume":"62","author":"J Ji","year":"2015","unstructured":"Ji J, Eggert T, Budhu A, Forgues M, Takai A, Dang H, et al. Hepatic stellate cell and monocyte interaction contributes to poor prognosis in hepatocellular carcinoma. Hepatol Baltim Md. 2015;62:481\u2013495","journal-title":"Hepatol Baltim Md"},{"key":"10838_CR131","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.canlet.2021.05.007","volume":"513","author":"M-Y Ke","year":"2021","unstructured":"Ke M-Y, Xu T, Fang Y, Ye Y-P, Li Z-J, Ren F-G, et al. Liver fibrosis promotes immune escape in hepatocellular carcinoma via GOLM1-mediated PD-L1 upregulation. Cancer Lett. 2021;513:14\u201325","journal-title":"Cancer Lett"},{"key":"10838_CR132","doi-asserted-by":"publisher","first-page":"16654","DOI":"10.3390\/ijms242316654","volume":"24","author":"T Mondal","year":"2023","unstructured":"Mondal T, Smith CI, Loffredo CA, Quartey R, Moses G, Howell CD, et al. Transcriptomics of MASLD Pathobiology in african american patients in the washington DC Area \u2020. Int J Mol Sci. 2023;24:16654","journal-title":"Int J Mol Sci"},{"key":"10838_CR133","doi-asserted-by":"publisher","first-page":"1188277","DOI":"10.3389\/fimmu.2023.1188277","volume":"14","author":"M Zhao","year":"2023","unstructured":"Zhao M, Huang H, He F, Fu X. Current insights into the hepatic microenvironment and advances in immunotherapy for hepatocellular carcinoma. Front Immunol. 2023;14:1188277","journal-title":"Front Immunol"},{"key":"10838_CR134","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1111\/jgh.16584","volume":"39","author":"SK Shin","year":"2024","unstructured":"Shin SK, Oh S, Chun S-K, Ahn M-J, Lee S-M, Kim K, et al. Immune signature and therapeutic approach of natural killer cell in chronic liver disease and hepatocellular carcinoma. J Gastroenterol Hepatol. 2024;39:1717\u20131727","journal-title":"J Gastroenterol Hepatol"},{"key":"10838_CR135","doi-asserted-by":"publisher","first-page":"4173","DOI":"10.3390\/ijms22084173","volume":"22","author":"M Longo","year":"2021","unstructured":"Longo M, Paolini E, Meroni M, Dongiovanni P. Remodeling of mitochondrial plasticity: the key switch from NAFLD\/NASH to HCC. Int J Mol Sci. 2021;22:4173","journal-title":"Int J Mol Sci"},{"key":"10838_CR136","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1002\/mc.23029","volume":"58","author":"Y-Y Guo","year":"2019","unstructured":"Guo Y-Y, Xu C, Fang Y, Wang C-E, Gao N, Wen Q, et al. High CYP2E1 activity aggravates hepatofibrosis by limiting macrophage polarization towards the M2 phenotype. Mol Carcinog. 2019;58:1481\u20131491","journal-title":"Mol Carcinog"},{"key":"10838_CR137","doi-asserted-by":"publisher","first-page":"288","DOI":"10.3390\/cells11020288","volume":"11","author":"J Massart","year":"2022","unstructured":"Massart J, Begriche K, Hartman JH, Fromenty B. role of mitochondrial cytochrome P450 2E1 in healthy and diseased liver. Cells. 2022;11:288","journal-title":"Cells"},{"key":"10838_CR138","doi-asserted-by":"publisher","first-page":"112199","DOI":"10.18632\/oncotarget.22937","volume":"8","author":"J Gao","year":"2017","unstructured":"Gao J, Wang G-J, Wang Z, Gao N, Li J, Zhang Y-F, et al. High CYP2E1 activity correlates with hepatofibrogenesis induced by nitrosamines. Oncotarget. 2017;8:112199\u2013112210","journal-title":"Oncotarget"},{"key":"10838_CR139","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1124\/jpet.117.245555","volume":"365","author":"J Gao","year":"2018","unstructured":"Gao J, Wang Z, Wang G-J, Zhang H-X, Gao N, Wang J, et al. Higher CYP2E1 activity correlates with hepatocarcinogenesis induced by diethylnitrosamine. J Pharmacol Exp Ther. 2018;365:398\u2013407","journal-title":"J Pharmacol Exp Ther"},{"key":"10838_CR140","doi-asserted-by":"publisher","first-page":"875","DOI":"10.3390\/cells9040875","volume":"9","author":"N Roehlen","year":"2020","unstructured":"Roehlen N, Crouchet E, Baumert TF. Liver fibrosis: mechanistic concepts and therapeutic perspectives. Cells. 2020;9:875","journal-title":"Cells"},{"key":"10838_CR141","doi-asserted-by":"publisher","first-page":"100","DOI":"10.3390\/cells8020100","volume":"8","author":"P Sharma","year":"2019","unstructured":"Sharma P, Sampath H. Mitochondrial DNA integrity: role in health and disease. Cells. 2019;8:100","journal-title":"Cells"},{"key":"10838_CR142","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2022.119233","volume":"1869","author":"S Liao","year":"2022","unstructured":"Liao S, Chen L, Song Z, He H. The fate of damaged mitochondrial DNA in the cell. Biochim Biophys Acta Mol Cell Res. 2022;1869: 119233","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"10838_CR143","doi-asserted-by":"publisher","DOI":"10.2174\/0118761429273223231124072223","volume":"17","author":"D Karati","year":"2024","unstructured":"Karati D, Kumar D. Molecular insight into the apoptotic mechanism of cancer cells: an explicative review. Curr Mol Pharmacol. 2024;17: e18761429273223","journal-title":"Curr Mol Pharmacol"},{"key":"10838_CR144","doi-asserted-by":"publisher","DOI":"10.2174\/0118761429269383231119062233","volume":"17","author":"A Ullah","year":"2024","unstructured":"Ullah A, Razzaq A, Alfaifi MY, Elbehairi SEI, Menaa F, Ullah N, et al. Sanguinarine attenuates lung cancer progression via oxidative stress-induced cell apoptosis. Curr Mol Pharmacol. 2024;17: e18761429269383","journal-title":"Curr Mol Pharmacol"},{"key":"10838_CR145","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.molmed.2023.08.001","volume":"29","author":"Z Che","year":"2023","unstructured":"Che Z, Zhou Z, Li S-Q, Gao L, Xiao J, Wong N-K. ROS\/RNS as molecular signatures of chronic liver diseases. Trends Mol Med. 2023;29:951\u2013967","journal-title":"Trends Mol Med"},{"key":"10838_CR146","doi-asserted-by":"publisher","first-page":"7858","DOI":"10.3390\/ijms25147858","volume":"25","author":"T Umezu","year":"2024","unstructured":"Umezu T, Mori T, Toyoda H, Kanekura K, Tamori A, Ochiya T, et al. Analysis of carcinogenic involvement of MicroRNA pattern in peripheral non-cancerous tissues and chronic viral liver injury. Int J Mol Sci. 2024;25:7858","journal-title":"Int J Mol Sci"},{"key":"10838_CR147","doi-asserted-by":"publisher","first-page":"6481","DOI":"10.3390\/ijms25126481","volume":"25","author":"LL Moore","year":"2024","unstructured":"Moore LL, Qu D, Sureban S, Mitchell S, Pitts K, Cooper N, et al. From inflammation to oncogenesis: tracing serum DCLK1 and miRNA signatures in chronic liver diseases. Int J Mol Sci. 2024;25:6481","journal-title":"Int J Mol Sci"},{"key":"10838_CR148","doi-asserted-by":"publisher","DOI":"10.1016\/j.jnutbio.2020.108479","volume":"85","author":"GR Romualdo","year":"2020","unstructured":"Romualdo GR, Prata GB, da Silva TC, Evangelista AF, Reis RM, Vinken M, et al. The combination of coffee compounds attenuates early fibrosis-associated hepatocarcinogenesis in mice: involvement of miRNA profile modulation. J Nutr Biochem. 2020;85: 108479","journal-title":"J Nutr Biochem"},{"key":"10838_CR149","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1177\/0023677215571192","volume":"49","author":"D Scholten","year":"2015","unstructured":"Scholten D, Trebicka J, Liedtke C, Weiskirchen R. The carbon tetrachloride model in mice. Lab Anim. 2015;49:4\u201311","journal-title":"Lab Anim"},{"key":"10838_CR150","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.666138","volume":"12","author":"Y-L Bao","year":"2021","unstructured":"Bao Y-L, Wang L, Pan H-T, Zhang T-R, Chen Y-H, Xu S-J, et al. Animal and organoid models of liver fibrosis. Front Physiol. 2021;12: 666138","journal-title":"Front Physiol"},{"key":"10838_CR151","doi-asserted-by":"publisher","first-page":"3389","DOI":"10.1073\/pnas.0409722102","volume":"102","author":"JS Campbell","year":"2005","unstructured":"Campbell JS, Hughes SD, Gilbertson DG, Palmer TE, Holdren MS, Haran AC, et al. Platelet-derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma. Proc Natl Acad Sci USA. 2005;102:3389\u20133394","journal-title":"Proc Natl Acad Sci USA"},{"key":"10838_CR152","doi-asserted-by":"publisher","first-page":"27406","DOI":"10.1074\/jbc.M101056200","volume":"276","author":"DG Gilbertson","year":"2001","unstructured":"Gilbertson DG, Duff ME, West JW, Kelly JD, Sheppard PO, Hofstrand PD, et al. Platelet-derived growth factor C (PDGF-C), a novel growth factor that binds to PDGF alpha and beta receptor. J Biol Chem. 2001;276:27406\u201327414","journal-title":"J Biol Chem"},{"key":"10838_CR153","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/35010579","volume":"2","author":"X Li","year":"2000","unstructured":"Li X, Pont\u00e9n A, Aase K, Karlsson L, Abramsson A, Uutela M, et al. PDGF-C is a new protease-activated ligand for the PDGF alpha-receptor. Nat Cell Biol. 2000;2:302\u2013309","journal-title":"Nat Cell Biol"},{"key":"10838_CR154","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12957-023-02938-6","volume":"21","author":"L Wang","year":"2023","unstructured":"Wang L, Chen K, Weng S, Xu H, Ren Y, Cheng Q, et al. PI3K pathway mutation predicts an activated immune microenvironment and better immunotherapeutic efficacy in head and neck squamous cell carcinoma. World J Surg Oncol. 2023;21:72","journal-title":"World J Surg Oncol"},{"key":"10838_CR155","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1172\/JCI20513","volume":"113","author":"Y Horie","year":"2004","unstructured":"Horie Y, Suzuki A, Kataoka E, Sasaki T, Hamada K, Sasaki J, et al. Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. J Clin Invest. 2004;113:1774\u201383","journal-title":"J Clin Invest"},{"key":"10838_CR156","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1073\/pnas.0308617100","volume":"101","author":"B Stiles","year":"2004","unstructured":"Stiles B, Wang Y, Stahl A, Bassilian S, Lee WP, Kim Y-J, et al. Liver-specific deletion of negative regulator Pten results in fatty liver and insulin hypersensitivity [corrected]. Proc Natl Acad Sci USA. 2004;101:2082\u20132087","journal-title":"Proc Natl Acad Sci USA"},{"key":"10838_CR157","first-page":"4253","volume":"43","author":"SD Vesselinovitch","year":"1983","unstructured":"Vesselinovitch SD, Mihailovich N. Kinetics of diethylnitrosamine hepatocarcinogenesis in the infant mouse. Cancer Res. 1983;43:4253\u20134259","journal-title":"Cancer Res"},{"key":"10838_CR158","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2024.134120","volume":"278","author":"X-T Fu","year":"2024","unstructured":"Fu X-T, Qie J-B, Chen J-F, Gao Z, Li X-G, Feng S-R, et al. Inhibition of SIRT1 relieves hepatocarcinogenesis via alleviating autophagy and inflammation. Int J Biol Macromol. 2024;278: 134120","journal-title":"Int J Biol Macromol"},{"key":"10838_CR159","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1097\/HEP.0000000000000801","volume":"80","author":"Z Peng","year":"2024","unstructured":"Peng Z, Wei G, Huang P, Matta H, Gao W, An P, et al. ASK1\/ p38 axis inhibition blocks the release of mitochondrial \u201cdanger signals\u201d from hepatocytes and suppresses progression to cirrhosis and liver cancer. Hepatol Baltim Md. 2024;80:346\u2013362","journal-title":"Hepatol Baltim Md"},{"key":"10838_CR160","doi-asserted-by":"publisher","first-page":"3906","DOI":"10.3390\/cancers14163906","volume":"14","author":"RA Glabman","year":"2022","unstructured":"Glabman RA, Choyke PL, Sato N. Cancer-associated fibroblasts: tumorigenicity and targeting for cancer therapy. Cancers. 2022;14:3906","journal-title":"Cancers"},{"key":"10838_CR161","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2024.103029","volume":"69","author":"Y Fu","year":"2024","unstructured":"Fu Y, Zhou X, Wang L, Fan W, Gao S, Zhang D, et al. Salvianolic acid B attenuates liver fibrosis by targeting Ecm1 and inhibiting hepatocyte ferroptosis. Redox Biol. 2024;69: 103029","journal-title":"Redox Biol"},{"key":"10838_CR162","first-page":"565","volume":"32","author":"ZG Yuan","year":"2024","unstructured":"Yuan ZG, Ye SL. Systemic therapeutic strategies for hepatocellular carcinoma: current status and prospects. Zhonghua Gan Zang Bing Za Zhi Zhonghua Ganzangbing Zazhi Chin J Hepatol. 2024;32:565\u2013571","journal-title":"Zhonghua Gan Zang Bing Za Zhi Zhonghua Ganzangbing Zazhi Chin J Hepatol"},{"key":"10838_CR163","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2022.100681","volume":"27","author":"J Yan","year":"2022","unstructured":"Yan J, Fang X, Feng Y, Cui X, Li F, Luo W, et al. Identification of key genes associated with the progression of liver fibrosis to hepatocellular carcinoma based on iTRAQ proteomics and GEO database. Ann Hepatol. 2022;27: 100681","journal-title":"Ann Hepatol"},{"key":"10838_CR164","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41568-019-0238-1","volume":"20","author":"E Sahai","year":"2020","unstructured":"Sahai E, Astsaturov I, Cukierman E, DeNardo DG, Egeblad M, Evans RM, et al. A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev Cancer. 2020;20:174\u2013186","journal-title":"Nat Rev Cancer"},{"key":"10838_CR165","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102684","volume":"73","author":"J Shen","year":"2024","unstructured":"Shen J, Hu R, Lin A, Jiang A, Tang B, Liu Z, et al. Characterization of second primary malignancies post CAR T-cell therapy: real-world insights from the two global pharmacovigilance databases of FAERS and VigiBase. EClinicalMedicine. 2024;73: 102684","journal-title":"EClinicalMedicine"},{"key":"10838_CR166","first-page":"18","volume":"7","author":"A Borogovac","year":"2024","unstructured":"Borogovac A, Siddiqi T. Advancing CAR T-cell therapy for chronic lymphocytic leukemia: exploring resistance mechanisms and the innovative strategies to overcome them. Cancer Drug Resist Alhambra Calif. 2024;7:18","journal-title":"Cancer Drug Resist Alhambra Calif"},{"key":"10838_CR167","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.634741","volume":"12","author":"C Zhou","year":"2021","unstructured":"Zhou C, Lin A, Cao M, Ding W, Mou W, Guo N, et al. Activation of the DDR pathway leads to the down-regulation of the TGF\u03b2 pathway and a better response to ICIs in patients with metastatic urothelial carcinoma. Front Immunol. 2021;12: 634741","journal-title":"Front Immunol"},{"key":"10838_CR168","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1152\/physrev.00048.2019","volume":"101","author":"G Biffi","year":"2021","unstructured":"Biffi G, Tuveson DA. Diversity and biology of cancer-associated fibroblasts. Physiol Rev. 2021;101:147\u2013176","journal-title":"Physiol Rev"},{"key":"10838_CR169","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nrgastro.2010.213","volume":"8","author":"T Luedde","year":"2011","unstructured":"Luedde T, Schwabe RF. NF-\u03baB in the liver\u2013linking injury, fibrosis and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2011;8:108\u2013118","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10838_CR170","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.canlet.2008.12.031","volume":"278","author":"J-M Wu","year":"2009","unstructured":"Wu J-M, Sheng H, Saxena R, Skill NJ, Bhat-Nakshatri P, Yu M, et al. NF-kappaB inhibition in human hepatocellular carcinoma and its potential as adjunct to sorafenib based therapy. Cancer Lett. 2009;278:145\u2013155","journal-title":"Cancer Lett"},{"key":"10838_CR171","first-page":"747","volume":"116","author":"J Wang","year":"2003","unstructured":"Wang J, Huang Q, Chen M. The role of NF-kappaB in hepatocellular carcinoma cell. Chin Med J (Engl). 2003;116:747\u2013752","journal-title":"Chin Med J (Engl)"},{"key":"10838_CR172","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1002\/biof.1324","volume":"43","author":"T Mehmood","year":"2017","unstructured":"Mehmood T, Maryam A, Zhang H, Li Y, Khan M, Ma T. Deoxyelephantopin induces apoptosis in HepG2 cells via oxidative stress, NF-\u03baB inhibition and mitochondrial dysfunction. BioFactors Oxf Engl. 2017;43:63\u201372","journal-title":"BioFactors Oxf Engl"},{"key":"10838_CR173","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.jhep.2015.04.018","volume":"63","author":"JU Marquardt","year":"2015","unstructured":"Marquardt JU, Gomez-Quiroz L, Arreguin Camacho LO, Pinna F, Lee Y-H, Kitade M, et al. Curcumin effectively inhibits oncogenic NF-\u03baB signaling and restrains stemness features in liver cancer. J Hepatol. 2015;63:661\u2013669","journal-title":"J Hepatol"},{"key":"10838_CR174","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/s41419-019-1881-x","volume":"10","author":"X Zhang","year":"2019","unstructured":"Zhang X, Lin C, Song J, Chen H, Chen X, Ren L, et al. Parkin facilitates proteasome inhibitor-induced apoptosis via suppression of NF-\u03baB activity in hepatocellular carcinoma. Cell Death Dis. 2019;10:719","journal-title":"Cell Death Dis"},{"key":"10838_CR175","first-page":"2","volume":"7","author":"P Spiliopoulou","year":"2024","unstructured":"Spiliopoulou P, Kaur P, Hammett T, Di Conza G, Lahn M. Targeting T regulatory (Treg) cells in immunotherapy-resistant cancers. Cancer Drug Resist Alhambra Calif. 2024;7:2","journal-title":"Cancer Drug Resist Alhambra Calif"},{"key":"10838_CR176","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/s41392-024-01823-2","volume":"9","author":"Y Zhou","year":"2024","unstructured":"Zhou Y, Tao L, Qiu J, Xu J, Yang X, Zhang Y, et al. Tumor biomarkers for diagnosis, prognosis and targeted therapy. Signal Transduct Target Ther. 2024;9:132","journal-title":"Signal Transduct Target Ther"},{"key":"10838_CR177","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s40139-013-0018-7","volume":"1","author":"X Liu","year":"2013","unstructured":"Liu X, Xu J, Brenner DA, Kisseleva T. Reversibility of liver fibrosis and inactivation of fibrogenic myofibroblasts. Curr Pathobiol Rep. 2013;1:209\u2013214","journal-title":"Curr Pathobiol Rep"},{"key":"10838_CR178","doi-asserted-by":"publisher","DOI":"10.1007\/s40139-013-0018-7","author":"Y Yang","year":"2025","unstructured":"Yang Y, Zhang Y, Wang L, He G, Yang X, Qing J. Targeting p97\/valosin-containing protein promotes hepatic stellate cell senescence and mitigates liver fibrosis. DNA Cell Biol. 2025. https:\/\/doi.org\/10.1007\/s40139-013-0018-7","journal-title":"DNA Cell Biol."},{"key":"10838_CR179","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202303710","volume":"13","author":"L Wang","year":"2024","unstructured":"Wang L, Zhou J, Wang J, Wang X, Dong H, Zhao L, et al. Hepatic stellate cell-targeting micelle nanomedicine for early diagnosis and treatment of liver fibrosis. Adv Healthc Mater. 2024;13: e2303710","journal-title":"Adv Healthc Mater"},{"key":"10838_CR180","doi-asserted-by":"publisher","DOI":"10.1016\/j.tice.2023.102118","volume":"82","author":"AA Sayed","year":"2023","unstructured":"Sayed AA, Soliman AM, Marzouk M, Mohammed FF, Desouky S. Bromelain mitigates liver fibrosis via targeting hepatic stellate cells in vitro and in vivo. Tissue Cell. 2023;82: 102118","journal-title":"Tissue Cell"},{"key":"10838_CR181","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/sj.cdd.4401979","volume":"14","author":"J Mann","year":"2007","unstructured":"Mann J, Oakley F, Akiboye F, Elsharkawy A, Thorne AW, Mann DA. Regulation of myofibroblast transdifferentiation by DNA methylation and MeCP2: implications for wound healing and fibrogenesis. Cell Death Differ. 2007;14:275\u2013285","journal-title":"Cell Death Differ"},{"key":"10838_CR182","doi-asserted-by":"publisher","first-page":"3954244","DOI":"10.1155\/2021\/3954244","volume":"2021","author":"W Wu","year":"2021","unstructured":"Wu W, Li L, Yang J, Li P, Hu Y, Zhang G, et al. Therapeutic effect of biejiaxiaozheng pills on carbon tetrachloride-induced hepatic fibrosis in rats through the NF-\u03baB\/Nrf2 pathway. Gastroenterol Res Pract. 2021;2021:3954244","journal-title":"Gastroenterol Res Pract"},{"key":"10838_CR183","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1093\/abbs\/gmy024","volume":"50","author":"D Li","year":"2018","unstructured":"Li D, Li W, Chen Y, Liu L, Ma D, Wang H, et al. Anti-fibrotic role and mechanism of Periplaneta americana extracts in CCl4-induced hepatic fibrosis in rats. Acta Biochim Biophys Sin. 2018;50:491\u2013498","journal-title":"Acta Biochim Biophys Sin"},{"key":"10838_CR184","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nature12681","volume":"505","author":"B-S Ding","year":"2014","unstructured":"Ding B-S, Cao Z, Lis R, Nolan DJ, Guo P, Simons M, et al. Divergent angiocrine signals from vascular niche balance liver regeneration and fibrosis. Nature. 2014;505:97\u2013102","journal-title":"Nature"},{"key":"10838_CR185","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.5858\/2000-124-1599-ROHC","volume":"124","author":"IR Wanless","year":"2000","unstructured":"Wanless IR, Nakashima E, Sherman M. Regression of human cirrhosis. Morphologic features and the genesis of incomplete septal cirrhosis. Arch Pathol Lab Med. 2000;124:1599\u2013607","journal-title":"Arch Pathol Lab Med"},{"key":"10838_CR186","doi-asserted-by":"publisher","first-page":"1218705","DOI":"10.3389\/fmed.2023.1218705","volume":"10","author":"I Manea","year":"2023","unstructured":"Manea I, Iacob R, Iacob S, Cerban R, Dima S, Oniscu G, et al. Liquid biopsy for early detection of hepatocellular carcinoma. Front Med. 2023;10:1218705","journal-title":"Front Med"},{"key":"10838_CR187","first-page":"1382","volume":"30","author":"ZH Fan","year":"2022","unstructured":"Fan ZH, Ren F. The role of circulating tumor DNA in the diagnosis and prognosis of hepatocellular carcinoma. Zhonghua Gan Zang Bing Za Zhi Zhonghua Ganzangbing Zazhi Chin J Hepatol. 2022;30:1382\u20131386","journal-title":"Zhonghua Gan Zang Bing Za Zhi Zhonghua Ganzangbing Zazhi Chin J Hepatol"},{"key":"10838_CR188","volume":"2014","author":"H Wang","year":"2014","unstructured":"Wang H, Hou L, Li A, Duan Y, Gao H, Song X. Expression of serum exosomal microRNA-21 in human hepatocellular carcinoma. BioMed Res Int. 2014;2014: 864894","journal-title":"BioMed Res Int"},{"key":"10838_CR189","doi-asserted-by":"publisher","DOI":"10.1038\/emm.2015.68","volume":"47","author":"W Sohn","year":"2015","unstructured":"Sohn W, Kim J, Kang SH, Yang SR, Cho J-Y, Cho HC, et al. Serum exosomal microRNAs as novel biomarkers for hepatocellular carcinoma. Exp Mol Med. 2015;47: e184","journal-title":"Exp Mol Med"},{"key":"10838_CR190","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0141448","volume":"10","author":"F Fornari","year":"2015","unstructured":"Fornari F, Ferracin M, Trer\u00e8 D, Milazzo M, Marinelli S, Galassi M, et al. Circulating microRNAs, miR-939, miR-595, miR-519d and miR-494, identify cirrhotic patients with HCC. PLoS One. 2015;10: e0141448","journal-title":"PLoS One"},{"key":"10838_CR191","doi-asserted-by":"publisher","first-page":"12060","DOI":"10.7150\/thno.48918","volume":"10","author":"Q Zhang","year":"2020","unstructured":"Zhang Q, Rong Y, Yi K, Huang L, Chen M, Wang F. Circulating tumor cells in hepatocellular carcinoma: single-cell based analysis, preclinical models, and clinical applications. Theranostics. 2020;10:12060\u201312071","journal-title":"Theranostics"},{"key":"10838_CR192","doi-asserted-by":"publisher","first-page":"4731","DOI":"10.1158\/0008-5472.CAN-17-2459","volume":"78","author":"L-N Qi","year":"2018","unstructured":"Qi L-N, Xiang B-D, Wu F-X, Ye J-Z, Zhong J-H, Wang Y-Y, et al. Circulating tumor cells undergoing EMT Provide a metric for diagnosis and prognosis of patients with hepatocellular carcinoma. Cancer Res. 2018;78:4731\u20134744","journal-title":"Cancer Res"},{"key":"10838_CR193","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.7150\/thno.15284","volume":"6","author":"S Wang","year":"2016","unstructured":"Wang S, Zhang C, Wang G, Cheng B, Wang Y, Chen F, et al. Aptamer-mediated transparent-biocompatible nanostructured surfaces for hepotocellular circulating tumor cells enrichment. Theranostics. 2016;6:1877\u20131886","journal-title":"Theranostics"},{"key":"10838_CR194","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S0140-6736(96)07642-8","volume":"349","author":"T Poynard","year":"1997","unstructured":"Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet Lond Engl. 1997;349:825\u201332","journal-title":"Lancet Lond Engl."},{"key":"10838_CR195","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/S0168-8278(00)00097-0","volume":"34","author":"T Poynard","year":"2001","unstructured":"Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c. J Hepatol. 2001;34:730\u2013739","journal-title":"J Hepatol"},{"key":"10838_CR196","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1046\/j.1440-1746.2000.0150121356.x","volume":"15","author":"I Merican","year":"2000","unstructured":"Merican I, Guan R, Amarapuka D, Alexander MJ, Chutaputti A, Chien RN, et al. Chronic hepatitis B virus infection in Asian countries. J Gastroenterol Hepatol. 2000;15:1356\u20131361","journal-title":"J Gastroenterol Hepatol"},{"key":"10838_CR197","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1055\/s-2001-12926","volume":"21","author":"Y Falck-Ytter","year":"2001","unstructured":"Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis. 2001;21:17\u201326","journal-title":"Semin Liver Dis"},{"key":"10838_CR198","first-page":"688","volume":"32","author":"D Chang","year":"2024","unstructured":"Chang D, Yang J, Li YB, Zhou XY, Ju SS. Current status and new advancements in molecular imaging of liver cancer. Zhonghua Gan Zang Bing Za Zhi Zhonghua Ganzangbing Zazhi Chin J Hepatol. 2024;32:688\u2013694","journal-title":"Zhonghua Gan Zang Bing Za Zhi Zhonghua Ganzangbing Zazhi Chin J Hepatol"},{"key":"10838_CR199","doi-asserted-by":"crossref","unstructured":"Subramanian K, Aggarwal P, Hall LT, Singh H, Takalkar AM, Mittal BR. Molecular Imaging of Hepatobiliary Cancers. In: Hall LT, (eds) Mol Imaging Ther [Internet]. Brisbane (AU): Exon Publications. 2023. [cited 2024 Dec 1]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK599135\/","DOI":"10.36255\/molecular-imaging-of-hepatobiliary-cancers"},{"key":"10838_CR200","doi-asserted-by":"publisher","first-page":"342","DOI":"10.3390\/bios12050342","volume":"12","author":"D Zhao","year":"2022","unstructured":"Zhao D, Cao J, Zhang L, Zhang S, Wu S. Targeted molecular imaging probes based on magnetic resonance imaging for hepatocellular carcinoma diagnosis and treatment. Biosensors. 2022;12:342","journal-title":"Biosensors"},{"key":"10838_CR201","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1002\/mef2.38","volume":"2","author":"K Xia","year":"2023","unstructured":"Xia K, Wang J. Recent advances of Transformers in medical image analysis: a comprehensive review. MedComm Fut Med. 2023;2:e38","journal-title":"MedComm Fut Med."},{"key":"10838_CR202","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1002\/mef2.43","volume":"2","author":"D-Q Wang","year":"2023","unstructured":"Wang D-Q, Feng L-Y, Ye J-G, Zou J-G, Zheng Y-F. Accelerating the integration of ChatGPT and other large-scale AI models into biomedical research and healthcare. MedComm Fut Med. 2023;2:e43","journal-title":"MedComm Fut Med."},{"key":"10838_CR203","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2024.108337","volume":"173","author":"Z Bo","year":"2024","unstructured":"Bo Z, Song J, He Q, Chen B, Chen Z, Xie X, et al. Application of artificial intelligence radiomics in the diagnosis, treatment, and prognosis of hepatocellular carcinoma. Comput Biol Med. 2024;173: 108337","journal-title":"Comput Biol Med"},{"key":"10838_CR204","doi-asserted-by":"publisher","first-page":"1237445","DOI":"10.3389\/fcell.2024.1237445","volume":"12","author":"X Yu","year":"2024","unstructured":"Yu X, Zhang H, Li J, Gu L, Cao L, Gong J, et al. Construction of a prognostic prediction model in liver cancer based on genes involved in integrin cell surface interactions pathway by multi-omics screening. Front Cell Dev Biol. 2024;12:1237445","journal-title":"Front Cell Dev Biol"},{"key":"10838_CR205","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.jhep.2023.05.039","volume":"79","author":"R Fan","year":"2023","unstructured":"Fan R, Chen L, Zhao S, Yang H, Li Z, Qian Y, et al. Novel, high accuracy models for hepatocellular carcinoma prediction based on longitudinal data and cell-free DNA signatures. J Hepatol. 2023;79:933\u2013944","journal-title":"J Hepatol"},{"issue":"24","key":"10838_CR206","first-page":"02480","volume":"S0168\u20138278","author":"E Crouchet","year":"2024","unstructured":"Crouchet E, Dachraoui M, J\u00fchling F, Roehlen N, Oudot MA, Durand SC, et al. Targeting the liver clock improves fibrosis by restoring TGF-\u03b2 signaling. J Hepatol. 2024;S0168\u20138278(24):02480\u201302482","journal-title":"J Hepatol"},{"key":"10838_CR207","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1369\/0022155415627681","volume":"64","author":"F Xu","year":"2016","unstructured":"Xu F, Liu C, Zhou D, Zhang L. TGF-\u03b2\/SMAD pathway and its regulation in hepatic fibrosis. J Histochem Cytochem Off J Histochem Soc. 2016;64:157\u2013167","journal-title":"J Histochem Cytochem Off J Histochem Soc"},{"key":"10838_CR208","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.semcancer.2021.04.003","volume":"85","author":"J Jiang","year":"2022","unstructured":"Jiang J. Hedgehog signaling mechanism and role in cancer. Semin Cancer Biol. 2022;85:107\u2013122","journal-title":"Semin Cancer Biol"},{"key":"10838_CR209","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.bbrc.2007.12.085","volume":"367","author":"C Kordes","year":"2008","unstructured":"Kordes C, Sawitza I, H\u00e4ussinger D. Canonical Wnt signaling maintains the quiescent stage of hepatic stellate cells. Biochem Biophys Res Commun. 2008;367:116\u2013123","journal-title":"Biochem Biophys Res Commun"},{"key":"10838_CR210","first-page":"960","volume":"9","author":"K Duspara","year":"2021","unstructured":"Duspara K, Bojanic K, Pejic JI, Kuna L, Kolaric TO, Nincevic V, et al. Targeting the Wnt signaling pathway in liver fibrosis for drug options: an update. J Clin Transl Hepatol. 2021;9:960\u2013971","journal-title":"J Clin Transl Hepatol"},{"key":"10838_CR211","first-page":"1642","volume":"71","author":"N Liu","year":"2022","unstructured":"Liu N, Wang X, Steer CJ, Song G. MicroRNA-206 promotes the recruitment of CD8+ T cells by driving M1 polarisation of Kupffer cells. Gut. 2022;71:1642\u20131655","journal-title":"Gut"},{"key":"10838_CR212","doi-asserted-by":"crossref","unstructured":"Gilgenkrantz H, Paradis V, Lotersztajn S. Cell metabolism-based therapy for liver fibrosis, repair, and hepatocellular carcinoma. Hepatol Baltim Md. 2023.","DOI":"10.1097\/HEP.0000000000000479"},{"key":"10838_CR213","doi-asserted-by":"publisher","DOI":"10.2174\/0118761429308361240823061634","volume":"17","author":"L Qiong","year":"2024","unstructured":"Qiong L, Shuyao X, Shan X, Qian F, Jiaying T, Yao X, et al. Recent advances in the glycolytic processes linked to tumor metastasis. Curr Mol Pharmacol. 2024;17: e18761429308361","journal-title":"Curr Mol Pharmacol"},{"key":"10838_CR214","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1111\/jgh.16221","volume":"38","author":"Y Dong","year":"2023","unstructured":"Dong Y, Liu Y, Liu X, Ma H, Liu Y, Lv G, et al. Multi-omics profiling of primary hepatic stellate cells from advanced liver fibrosis patients reveals distinctive molecular signatures. J Gastroenterol Hepatol. 2023;38:1416\u20131425","journal-title":"J Gastroenterol Hepatol"},{"key":"10838_CR215","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1727","volume":"14","author":"S Yang","year":"2024","unstructured":"Yang S, Zheng L, Li L, Zhang J, Wang J, Zhao H, et al. Integrative multiomics analysis identifies molecular subtypes and potential targets of hepatocellular carcinoma. Clin Transl Med. 2024;14: e1727","journal-title":"Clin Transl Med"},{"key":"10838_CR216","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ccell.2023.11.010","volume":"42","author":"Y Sun","year":"2024","unstructured":"Sun Y, Wu P, Zhang Z, Wang Z, Zhou K, Song M, et al. Integrated multi-omics profiling to dissect the spatiotemporal evolution of metastatic hepatocellular carcinoma. Cancer Cell. 2024;42:135-156.e17","journal-title":"Cancer Cell"},{"key":"10838_CR217","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3390\/genes10020087","volume":"10","author":"B Mirza","year":"2019","unstructured":"Mirza B, Wang W, Wang J, Choi H, Chung NC, Ping P. Machine learning and integrative analysis of biomedical big data. Genes. 2019;10:87","journal-title":"Genes"},{"key":"10838_CR218","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1038\/s41591-022-01850-y","volume":"28","author":"L Niu","year":"2022","unstructured":"Niu L, Thiele M, Geyer PE, Rasmussen DN, Webel HE, Santos A, et al. Noninvasive proteomic biomarkers for alcohol-related liver disease. Nat Med. 2022;28:1277\u20131287","journal-title":"Nat Med"},{"key":"10838_CR219","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.15626","volume":"3","author":"GN Ioannou","year":"2020","unstructured":"Ioannou GN, Tang W, Beste LA, Tincopa MA, Su GL, Van T, et al. Assessment of a deep learning model to predict hepatocellular carcinoma in patients with hepatitis C cirrhosis. JAMA Netw Open. 2020;3: e2015626","journal-title":"JAMA Netw Open"},{"key":"10838_CR220","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2022.869263","volume":"9","author":"A Lin","year":"2022","unstructured":"Lin A, Qi C, Li M, Guan R, Imyanitov EN, Mitiushkina NV, et al. Deep learning analysis of the adipose tissue and the prediction of prognosis in colorectal cancer. Front Nutr. 2022;9: 869263","journal-title":"Front Nutr"},{"key":"10838_CR221","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12943-024-02062-3","volume":"23","author":"D-Z Guo","year":"2024","unstructured":"Guo D-Z, Zhang X, Zhang S-Q, Zhang S-Y, Zhang X-Y, Yan J-Y, et al. Single-cell tumor heterogeneity landscape of hepatocellular carcinoma: unraveling the pro-metastatic subtype and its interaction loop with fibroblasts. Mol Cancer. 2024;23:157","journal-title":"Mol Cancer"},{"key":"10838_CR222","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1002\/1878-0261.13190","volume":"16","author":"T Wang","year":"2022","unstructured":"Wang T, Dang N, Tang G, Li Z, Li X, Shi B, et al. Integrating bulk and single-cell RNA sequencing reveals cellular heterogeneity and immune infiltration in hepatocellular carcinoma. Mol Oncol. 2022;16:2195\u20132213","journal-title":"Mol Oncol"},{"key":"10838_CR223","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.378","volume":"4","author":"S Cheng","year":"2023","unstructured":"Cheng S, Zou Y, Zhang M, Bai S, Tao K, Wu J, et al. Single-cell RNA sequencing reveals the heterogeneity and intercellular communication of hepatic stellate cells and macrophages during liver fibrosis. MedComm. 2023;4: e378","journal-title":"MedComm"},{"key":"10838_CR224","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/s41586-019-1631-3","volume":"575","author":"P Ramachandran","year":"2019","unstructured":"Ramachandran P, Dobie R, Wilson-Kanamori JR, Dora EF, Henderson BEP, Luu NT, et al. Resolving the fibrotic niche of human liver cirrhosis at single-cell level. Nature. 2019;575:512\u2013518","journal-title":"Nature"},{"key":"10838_CR225","doi-asserted-by":"crossref","unstructured":"Jeong J-M, Choi SE, Shim Y-R, Kim H-H, Lee Y-S, Yang K, et al. CX 3 CR1 + macrophages interact with HSCs to promote HCC through CD8 + T-cell suppression. Hepatol Baltim Md. 2024.","DOI":"10.1097\/HEP.0000000000001021"},{"key":"10838_CR226","doi-asserted-by":"publisher","first-page":"5801","DOI":"10.3390\/ijms22115801","volume":"22","author":"K Oura","year":"2021","unstructured":"Oura K, Morishita A, Tani J, Masaki T. Tumor immune microenvironment and immunosuppressive therapy in hepatocellular carcinoma: a review. Int J Mol Sci. 2021;22:5801","journal-title":"Int J Mol Sci"},{"key":"10838_CR227","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","volume":"15","author":"DE Johnson","year":"2018","unstructured":"Johnson DE, O\u2019Keefe RA, Grandis JR. Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer. Nat Rev Clin Oncol. 2018;15:234\u2013248","journal-title":"Nat Rev Clin Oncol"},{"key":"10838_CR228","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1158\/2159-8290.CD-24-0002","volume":"14","author":"J Prakash","year":"2024","unstructured":"Prakash J, Shaked Y. The interplay between extracellular matrix remodeling and cancer therapeutics. Cancer Discov. 2024;14:1375\u20131388","journal-title":"Cancer Discov"},{"key":"10838_CR229","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1001\/jamaoncol.2023.2677","volume":"10","author":"S Cappuyns","year":"2024","unstructured":"Cappuyns S, Corbett V, Yarchoan M, Finn RS, Llovet JM. Critical appraisal of guideline recommendations on systemic therapies for advanced hepatocellular carcinoma: a review. JAMA Oncol. 2024;10:395\u2013404","journal-title":"JAMA Oncol"},{"key":"10838_CR230","doi-asserted-by":"publisher","first-page":"3073","DOI":"10.7150\/ijms.46686","volume":"17","author":"W Xu","year":"2020","unstructured":"Xu W, Zhao Z-Y, An Q-M, Dong B, Lv A, Li C-P, et al. Comprehensive comparison of patient-derived xenograft models in hepatocellular carcinoma and metastatic liver cancer. Int J Med Sci. 2020;17:3073\u20133081","journal-title":"Int J Med Sci"},{"key":"10838_CR231","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.stem.2021.04.005","volume":"28","author":"A Marsee","year":"2021","unstructured":"Marsee A, Roos FJM, Verstegen MMA, Gehart H, de Koning E, et al. HPB organoid consortium, building consensus on definition and nomenclature of hepatic, pancreatic, and biliary organoids. Cell Stem Cell. 2021;28:816\u201332","journal-title":"Cell Stem Cell"},{"key":"10838_CR232","doi-asserted-by":"publisher","DOI":"10.1016\/j.crmeth.2024.100778","volume":"4","author":"G Bi","year":"2024","unstructured":"Bi G, Zhang X, Li W, Lu X, He X, Li Y, et al. Modeling alcohol-associated liver disease in humans using adipose stromal or stem cell-derived organoids. Cell Rep Methods. 2024;4: 100778","journal-title":"Cell Rep Methods"},{"key":"10838_CR233","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.jhep.2024.01.002","volume":"80","author":"S Osonoi","year":"2024","unstructured":"Osonoi S, Takebe T. Organoid-guided precision hepatology for metabolic liver disease. J Hepatol. 2024;80:805\u2013821","journal-title":"J Hepatol"},{"key":"10838_CR234","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.3390\/cells12212514","volume":"12","author":"Y Yoon","year":"2023","unstructured":"Yoon Y, Gong SC, Kim MY, Baik SK, Hong J-E, Rhee K-J, et al. Generation of fibrotic liver organoids using hepatocytes, primary liver sinusoidal endothelial cells, hepatic stellate cells, and macrophages. Cells. 2023;12:2514","journal-title":"Cells"},{"key":"10838_CR235","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105608","volume":"169","author":"A Brooks","year":"2021","unstructured":"Brooks A, Liang X, Zhang Y, Zhao C-X, Roberts MS, Wang H, et al. Liver organoid as a 3D in vitro model for drug validation and toxicity assessment. Pharmacol Res. 2021;169: 105608","journal-title":"Pharmacol Res"},{"key":"10838_CR236","doi-asserted-by":"publisher","first-page":"1160053","DOI":"10.3389\/fmed.2023.1160053","volume":"10","author":"S Wu","year":"2023","unstructured":"Wu S, Wang X, Xing W, Li F, Liang M, Li K, et al. An update on animal models of liver fibrosis. Front Med. 2023;10:1160053","journal-title":"Front Med"},{"key":"10838_CR237","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/978-1-4939-2297-0_8","volume":"1267","author":"JM Caviglia","year":"2015","unstructured":"Caviglia JM, Schwabe RF. Mouse models of liver cancer. Methods Mol Biol Clifton NJ. 2015;1267:165\u2013183","journal-title":"Methods Mol Biol Clifton NJ"},{"key":"10838_CR238","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/hep.29405","volume":"67","author":"J Zhang","year":"2018","unstructured":"Zhang J, Li Z, Liu L, Wang Q, Li S, Chen D, et al. Long noncoding RNA TSLNC8 is a tumor suppressor that inactivates the interleukin-6\/STAT3 signaling pathway. Hepatol Baltim Md. 2018;67:171\u2013187","journal-title":"Hepatol Baltim Md"},{"key":"10838_CR239","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1002\/hep.30795","volume":"71","author":"Y Wei","year":"2020","unstructured":"Wei Y, Chen X, Liang C, Ling Y, Yang X, Ye X, et al. A noncoding regulatory RNAs network driven by Circ-CDYL acts specifically in the early stages hepatocellular carcinoma. Hepatol Baltim Md. 2020;71:130\u2013147","journal-title":"Hepatol Baltim Md"},{"key":"10838_CR240","doi-asserted-by":"publisher","first-page":"17775","DOI":"10.1002\/jcp.28403","volume":"234","author":"Z-Y Wang","year":"2019","unstructured":"Wang Z-Y, Zhu Z, Wang H-F, Qin B, Liu J, Yao X-H, et al. Downregulation of circDYNC1H1 exhibits inhibitor effect on cell proliferation and migration in hepatocellular carcinoma through miR-140-5p. J Cell Physiol. 2019;234:17775\u201317785","journal-title":"J Cell Physiol"},{"key":"10838_CR241","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/j.jhep.2018.01.012","volume":"68","author":"J Yu","year":"2018","unstructured":"Yu J, Xu Q-G, Wang Z-G, Yang Y, Zhang L, Ma J-Z, et al. Circular RNA cSMARCA5 inhibits growth and metastasis in hepatocellular carcinoma. J Hepatol. 2018;68:1214\u20131227","journal-title":"J Hepatol"},{"key":"10838_CR242","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.bbrc.2018.04.041","volume":"500","author":"W Jiang","year":"2018","unstructured":"Jiang W, Wen D, Gong L, Wang Y, Liu Z, Yin F. Circular RNA hsa_circ_0000673 promotes hepatocellular carcinoma malignance by decreasing miR-767-3p targeting SET. Biochem Biophys Res Commun. 2018;500:211\u2013216","journal-title":"Biochem Biophys Res Commun"},{"key":"10838_CR243","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.ymthe.2016.10.004","volume":"25","author":"M Zeybel","year":"2017","unstructured":"Zeybel M, Luli S, Sabater L, Hardy T, Oakley F, Leslie J, et al. A proof-of-concept for epigenetic therapy of tissue fibrosis: inhibition of liver fibrosis progression by 3-deazaneplanocin A. Mol Ther J Am Soc Gene Ther. 2017;25:218\u2013231","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"10838_CR244","doi-asserted-by":"publisher","first-page":"9593254","DOI":"10.1155\/2020\/9593254","volume":"2020","author":"MH Yousef","year":"2020","unstructured":"Yousef MH, El-Fawal HAN, Abdelnaser A. Hepigenetics: a review of epigenetic modulators and potential therapies in hepatocellular carcinoma. BioMed Res Int. 2020;2020:9593254","journal-title":"BioMed Res Int"},{"key":"10838_CR245","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3390\/cancers10010008","volume":"10","author":"K-Y Liu","year":"2018","unstructured":"Liu K-Y, Wang L-T, Hsu S-H. Modification of epigenetic histone acetylation in hepatocellular carcinoma. Cancers. 2018;10:8","journal-title":"Cancers"},{"key":"10838_CR246","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/s41583-023-00779-6","volume":"25","author":"AL Young","year":"2024","unstructured":"Young AL, Oxtoby NP, Garbarino S, Fox NC, Barkhof F, Schott JM, et al. Data-driven modelling of neurodegenerative disease progression: thinking outside the black box. Nat Rev Neurosci. 2024;25:111\u2013130","journal-title":"Nat Rev Neurosci"},{"key":"10838_CR247","doi-asserted-by":"publisher","first-page":"5382","DOI":"10.1007\/s00330-022-08610-z","volume":"32","author":"G Pontillo","year":"2022","unstructured":"Pontillo G, Penna S, Cocozza S, Quarantelli M, Gravina M, Lanzillo R, et al. Stratification of multiple sclerosis patients using unsupervised machine learning: a single-visit MRI-driven approach. Eur Radiol. 2022;32:5382\u20135391","journal-title":"Eur Radiol"},{"key":"10838_CR248","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1164\/rccm.201908-1600OC","volume":"201","author":"AL Young","year":"2020","unstructured":"Young AL, Bragman FJS, Rangelov B, Han MK, Galb\u00e1n CJ, Lynch DA, et al. Disease progression modeling in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2020;201:294\u2013302","journal-title":"Am J Respir Crit Care Med"},{"key":"10838_CR249","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1038\/s41467-021-22265-2","volume":"12","author":"A Eshaghi","year":"2021","unstructured":"Eshaghi A, Young AL, Wijeratne PA, Prados F, Arnold DL, Narayanan S, et al. Identifying multiple sclerosis subtypes using unsupervised machine learning and MRI data. Nat Commun. 2021;12:2078","journal-title":"Nat Commun"},{"key":"10838_CR250","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.656115","volume":"12","author":"S Wang","year":"2021","unstructured":"Wang S, Tang C, Zhao H, Shen P, Lin C, Zhu Y, et al. Network pharmacological analysis and experimental validation of the mechanisms of action of Si-Ni-san against liver fibrosis. Front Pharmacol. 2021;12: 656115","journal-title":"Front Pharmacol"},{"key":"10838_CR251","doi-asserted-by":"publisher","first-page":"9202128","DOI":"10.1155\/2022\/9202128","volume":"2022","author":"X Cheng","year":"2022","unstructured":"Cheng X, Han Z-X, Su Z-J, Zhang F-L, Li B-P, Jiang Z-R, et al. Network pharmacology-based exploration on the intervention of qinghao biejia decoction on the inflammation-carcinoma transformation process of chronic liver disease via MAPK and PI3k\/AKT pathway. BioMed Res Int. 2022;2022:9202128","journal-title":"BioMed Res Int"},{"key":"10838_CR252","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13020-019-0249-6","volume":"14","author":"Y Luo","year":"2019","unstructured":"Luo Y, Feng Y, Song L, He G-Q, Li S, Bai S-S, et al. A network pharmacology-based study on the anti-hepatoma effect of Radix Salviae Miltiorrhizae. Chin Med. 2019;14:27","journal-title":"Chin Med"},{"key":"10838_CR253","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.2147\/DDDT.S450324","volume":"18","author":"B Cai","year":"2024","unstructured":"Cai B, Qi M, Zhang X, Zhang D. Integrating network pharmacology with in vitro experiments to validate the efficacy of celastrol against hepatocellular carcinoma through ferroptosis. Drug Des Devel Ther. 2024;18:3121\u20133141","journal-title":"Drug Des Devel Ther"},{"key":"10838_CR254","doi-asserted-by":"publisher","first-page":"2871","DOI":"10.1002\/ijc.33245","volume":"147","author":"D-V Phan","year":"2020","unstructured":"Phan D-V, Chan C-L, Li A-HA, Chien T-Y, Nguyen V-C. Liver cancer prediction in a viral hepatitis cohort: A deep learning approach. Int J Cancer. 2020;147:2871\u20138","journal-title":"Int J Cancer."},{"key":"10838_CR255","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2020.105551","volume":"196","author":"S Hashem","year":"2020","unstructured":"Hashem S, ElHefnawi M, Habashy S, El-Adawy M, Esmat G, Elakel W, et al. Machine learning prediction models for diagnosing hepatocellular carcinoma with HCV-related chronic liver disease. Comput Methods Programs Biomed. 2020;196: 105551","journal-title":"Comput Methods Programs Biomed"},{"key":"10838_CR256","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/s41746-023-00976-8","volume":"7","author":"KH Lee","year":"2024","unstructured":"Lee KH, Choi GH, Yun J, Choi J, Goh MJ, Sinn DH, et al. Machine learning-based clinical decision support system for treatment recommendation and overall survival prediction of hepatocellular carcinoma: a multi-center study. NPJ Digit Med. 2024;7:2","journal-title":"NPJ Digit Med"},{"key":"10838_CR257","volume":"11","author":"Y Sun","year":"2024","unstructured":"Sun Y, Liu Y, Li R, Zhang C, Wu M, Zhang X, et al. Multifunctional biomimetic nanocarriers for dual-targeted immuno-gene therapy against hepatocellular carcinoma. Adv Sci Weinh Baden-Wurtt Ger. 2024;11: e2400951","journal-title":"Adv Sci Weinh Baden-Wurtt Ger"},{"key":"10838_CR258","doi-asserted-by":"publisher","first-page":"8255","DOI":"10.1007\/s12274-022-4462-8","volume":"15","author":"S Feng","year":"2022","unstructured":"Feng S, Ni P, Gong Y, Geng B, Li H, Miao C, et al. Synergistic anti-tumor therapy by a homotypic cell membrane-cloaked biomimetic nanocarrier with exceptionally potent activity against hepatic carcinoma. Nano Res. 2022;15:8255\u20138269","journal-title":"Nano Res"},{"key":"10838_CR259","doi-asserted-by":"publisher","first-page":"20739","DOI":"10.1021\/acsnano.2c07796","volume":"16","author":"Y Hao","year":"2022","unstructured":"Hao Y, Song K, Tan X, Ren L, Guo X, Zhou C, et al. Reactive oxygen species-responsive polypeptide drug delivery system targeted activated hepatic stellate cells to ameliorate liver fibrosis. ACS Nano. 2022;16:20739\u201320757","journal-title":"ACS Nano"},{"key":"10838_CR260","volume":"9","author":"J Zhang","year":"2022","unstructured":"Zhang J, Lin Y, Lin Z, Wei Q, Qian J, Ruan R, et al. Stimuli-responsive nanoparticles for controlled drug delivery in synergistic cancer immunotherapy. Adv Sci Weinh Baden-Wurtt Ger. 2022;9: e2103444","journal-title":"Adv Sci Weinh Baden-Wurtt Ger"},{"key":"10838_CR261","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2023.122213","volume":"301","author":"H Yan","year":"2023","unstructured":"Yan H, Xu P, Ma H, Li Y, Zhang R, Cong H, et al. Enzyme-triggered transcytosis of drug carrier system for deep penetration into hepatoma tumors. Biomaterials. 2023;301: 122213","journal-title":"Biomaterials"},{"key":"10838_CR262","doi-asserted-by":"publisher","unstructured":"Zhang J, Zhang T, Zhang Z, Jia Q, Chen J, Li J, et al. The dual\u2010target nanoparticles with ROS sensitivity inhibit the hedgehog signaling pathway and decrease oxidative stress in activated hepatic stellate cells to alleviate liver fibrosis. [cited 2024 Dec 1]; Available from: https:\/\/doi.org\/10.1002\/adfm.202404658","DOI":"10.1002\/adfm.202404658"},{"key":"10838_CR263","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202308413","volume":"62","author":"W Chen","year":"2023","unstructured":"Chen W, Li Y, Liu C, Kang Y, Qin D, Chen S, et al. In situ engineering of tumor-associated macrophages via a nanodrug-delivering-drug (\u03b2-Elemene@Stanene) strategy for enhanced cancer chemo-immunotherapy. Angew Chem Int Ed Engl. 2023;62: e202308413","journal-title":"Angew Chem Int Ed Engl"},{"key":"10838_CR264","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202302865","volume":"13","author":"W Luo","year":"2024","unstructured":"Luo W, Zeng Y, Song Q, Wang Y, Yuan F, Li Q, et al. Strengthening the combinational immunotherapy from modulating the tumor inflammatory environment via hypoxia-responsive nanogels. Adv Healthc Mater. 2024;13: e2302865","journal-title":"Adv Healthc Mater"},{"key":"10838_CR265","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1007\/s40820-020-00482-6","volume":"12","author":"W Mu","year":"2020","unstructured":"Mu W, Chu Q, Liu Y, Zhang N. A review on nano-based drug delivery system for cancer chemoimmunotherapy. Nano Micro Lett. 2020;12:142","journal-title":"Nano Micro Lett"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-025-10838-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-025-10838-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-025-10838-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T00:16:08Z","timestamp":1757204168000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-025-10838-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":265,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10838"],"URL":"https:\/\/doi.org\/10.1007\/s12072-025-10838-y","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"21 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Anqi Lin, Minying Xiong, Bufu Tang, Aimin Jiang, Junyi Shen, Zaoqu Liu, Quan Cheng, Jian Zhang, Peng Luo have declared that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}